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Abstract 
Aims  
(1) To evaluate various predictors for a higher diagnostic yield in bronchoscopy 
(2) To evaluate different combinations of sampling techniques in bronchoscopy of 
endobronchial visible lesions and peripheral lesions not visible by bronchoscopy  
(3) To evaluate endobronchial ultrasound (EBUS) with a rotating miniprobe for 
localisation of peripheral lesions in a real-life situation among pulmonologists at 
various levels of expertise  
Methods 
I: A retrospective cohort study evaluated the results in the study centre before the 
introduction of EBUS. The study searched for predictors of a higher diagnostic yield 
and evaluated different combinations of sampling techniques. All 1438 
bronchoscopies performed in 2003 and 2004 at Haukeland University Hospital, 
Bergen, Norway, were retrospectively reviewed and 363 patients with proven 
malignant lung disease were included in the study. Sex, age, endobronchial visibility, 
location (lobe), distance from the carina and tumour size were evaluated as possible 
predictors for a higher detection rate for cancer. Sampling techniques performed were 
biopsy, transbronchial needle aspiration (TBNA), brushing, small volume lavage 
(SVL), and aspiration of fluid from the entire procedure. The predictors of a higher 
detection rate were analysed in bivariate analyses and in multivariate logistic 
regression. McNemars test compared different combinations of sampling techniques. 
A cost-minimisation analysis evaluated different combinations of sampling 
techniques for visible lesions. 
II: A prospective open randomised trial evaluated EBUS for peripheral lesions and 
searched for the optimal combination of sampling techniques in peripheral lesions. 
The study period was from 2005 to 2008 at Haukeland University Hospital and 
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Aalesund Hospital, Norway. The included 264 patients had peripheral lesions on the 
CT scan and no obvious endobronchial visible tumour on bronchoscopy. A simple 
randomisation without stratification assigned the patients to either EBUS or 
conventional bronchoscopy without EBUS. EBUS was performed with a 1.7 mm 
rotating probe with guide sheath. The study protocol recommended fluoroscopy for 
both study arms. An intention-to-treat analysis evaluated EBUS and a multivariate 
analysis was performed to avoid confounding. A cost-effectiveness analysis evaluated 
different combinations of biopsy, brushing, TBNA and washing. 
Results 
The detection rate for cancer in the retrospective study was 17 % in patients with no 
endobronchial visible lesions, 34 % in patients with endobronchial constriction or 
compression and 77 % in patients with endobronchial visible lesions. The multivariate 
logistic regression analysis retained endobronchial visibility and size as significantly 
predictors of a higher detection rate for cancer. Biopsy and brushing combined with 
endobronchial needle aspiration (EBNA) was the most economical combination of 
sampling techniques for endobronchial lesions in a cost-minimisation analysis.   
The detection rate for cancer in the prospective study was 36 % in the EBUS group 
and 44 % in the non-EBUS group (ns). The prospective study included only patients 
without endobronchial visible lesions. There was a significant interaction between 
size and randomisation to EBUS. Patients with lesions below 3 cm had a significantly 
higher detection rate in the non-EBUS group. Lesions visualised by EBUS had a 
higher detection rate for cancer than lesions not visualised by EBUS (62 % vs. 19 %, 
p<0.01). The cost of one additional positive sample was 1211 euro when brushing 
was added to biopsy. Based on a willingness to pay of 2800 euro for an additional 
positive sample, biopsy and brushing was the most cost-effective combination of 
sampling techniques for lesions not visible by bronchoscopy. The addition of TBNA 
or washing had cost-effectiveness ratios above 2800 euro.  
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Conclusions 
1) Endobronchial visibility and lesion size were significant predictors of a higher 
detection rate for cancer in bronchoscopy. 
2) For visible lesions, biopsy and brushing combined with EBNA was the most 
economical combination of sampling techniques. For lesions not visible by 
bronchoscopy, biopsy together with brushing was the most cost-effective combination 
of sampling techniques. 
3) Overall, EBUS did not increase the detection rate for cancer in peripheral lesions 
when pulmonologists at various levels of expertise performed the bronchoscopies. 
However, visualisation by EBUS predicted a high detection rate for cancer. 
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1. TERMS AND ABBREVIATIONS 
1.1 Terms 
 When the sample size is calculated,  is the 
predefined accepted probability for a type I 
mistake (a false positive result).  is set as 0.05. 
  In sample size calculations  is the predefined 
accepted probability for a type II mistake (a 
false-negative result due to insufficient study 
size).  is usually set as 0.1 or 0.2. 
Cohort study  A study that follows a group of people for a 
period of time. 
Confidence interval An estimate of the variability in the data. The 
estimate measures the range of values with  
above a specified level. A 95 % confidence 
interval is the range of values with  above 
0.05. 
Cost-effectiveness analysis An analysis of alternative strategies that 
compares the increase in cost to the increase in 
effectiveness for the alternatives in contrast to a 
reference strategy. 
Cost-minimisation analysis An analysis that reveals the least costly 
strategy. 
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Decision tree A figure in a decision analysis that displays the 
actual strategies with all possible outcomes.  
Detection rate The percentage of pathological cases correctly 
detected by an investigation. The detection rate 
for cancer is analogue to sensitivity for cancer. 
Diagnostic yield The ability to detect distinct diagnoses 
compared to a gold standard. The diagnostic 
yield can include benign and malignant disease.  
Incremental cost-effectiveness ratio The increase in the cost divided by the increase 
in the effectiveness. If the diagnostic yield 
defines the effectiveness, the incremental cost-
effectiveness ratio will be the price for one 
additional positive sample.  
Likelihood ratio The likelihood ratio is sensitivity divided by (1-
spesifisity).  
Logistic regression Logistic regression describes the probability (p) 
for an outcome based on the value of a variable 
(x). The current study used logistic regression 
to find significant predictors of the diagnostic 
yield in bronchoscopy.  Logistic regression is 
based on the log odds (log odds is loge(p/(1-
p))). The logistic function e+x/(1+ e+x) 
describes the probability for outcome=1 in a 
group. Logit = loge(p/(1-p)) = +x 
Logistic model The logistic model defines the logistic function: 
e+x/(1+ e+x).  is a constant and  is the 
coefficient for x. X is a significant predictor for 
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the outcome when the confidence interval for  
not includes 0 and the confidence interval for e 
does not include 1.   
Multiple regression Multiple regression is a logistic regression 
analysis that analyses the effect of multiple 
variables on the outcome. For each variable, the 
analysis reveals a  that is the effect of that 
variable. Each variable has a significant effect 
on the outcome when the 95 % confidence 
interval for  of the variable does not include 
zero (and the confidence interval for e does not 
include 1). 
Odds The proportion with outcome=1 (p) divided by 
the proportion with outcome=0 (1-p) in a 
group. (p/(1-p)) 
Odds Ratio The odds in one group divided by the odds in 
another group. 
Open randomised trial A trial where the allocation to different 
interventions is random, but the patient and the 
investigator are aware of the allocation.  
p-value The p value represents the probability for a type 
1 mistake in the study. 
Power The power is the study’s ability to detect a 
difference and thus to reject the null hypothesis 
and to avoid a type 2 mistake. Power=1- . A 
usual desired power of a study is at least 80 % 
or 90 %.  
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Predictive value The proportion of patients with disease when a 
test is positive is the positive predictive value 
of a test. The negative predictive value of the 
test is the proportion with no disease when the 
test is negative.  
Prospective study A study that starts at a specific date and that 
includes and follows patients forward in time 
until the end of inclusion and the end of follow 
up. The prospective study can study cause and 
effect. 
Randomised trial The selection of interventions is random.  
Retrospective study A study that selects patients and register 
variables from a defined period prior to the start 
up date. Retrospective studies can describe the 
effect of different variables on each other, but 
are not able to settle cause and effect.  
Sensitivity The sensitivity is the number with positive test 
and proven disease divided by all with proven 
disease. 
Specificity Specificity is the number with negative test and 
no proven disease divided by all with no proven 
disease. Together with sensitivity, specificity 
displays the validity of the test 
Solitary pulmonary nodule A nodule surrounded on all sides by healthy 
pulmonary parenchyma.  
Standard deviation The standard deviation describes the variation 
from the average value. It is calculated as the 
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square root of the variance. (The variance is the 
sum of squared deviations from the mean). 95 
% of the values in the dataset will be within 
1.96 standard deviations below the mean and 
1.96 standard deviations above the mean in a 
perfect Gauss curve. 
Type I mistake The 0 hypothesis is rejected although it is true. 
(False positive.)  
Type II mistake The 0 hypothesis is not rejected although it is 
false. (False negative.)   
Willingness to pay In cost-effectiveness analyses, the willingness 
to pay is the amount of money reasonable to 
pay for an increase in the outcome with one 
unit. For example, the price can be for one 
additional quality adjusted life year (QALY). 
When the diagnostic yield is the outcome, the 
willingness to pay is the accepted price for one 
additional positive sample.  
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1.2 Abbreviations 
ATS    American thoracic society 
BAL   Bronchoalveolar lavage 
CONSORT  Consolidated standards of reporting trials 
CT   Computed tomography 
DRG   Diagnosis related group 
EBNA  Endobronchial needle aspiration 
EBUS   Endobronchial ultrasound 
EGFR   Epidermal growth factor receptor 
ERS   European respiratory society 
ICER   Incremental cost-effectiveness ratio 
MHz   Megahertz 
NOK   Norwegian kroner 
NS   Not significant 
PET   Positron emission tomography 
PhD   Philosophiae doctor 
QALY  Quality adjusted life years 
SE   Standard error 
SNOMED  Systemised nomenclature of medicine 
   20 
SPECT  Single photon emission computed tomography 
STARD  Standards for reporting of diagnostic accuracy 
SVL   Small volume lavage 
TBNA  Transbronchial fine-needle aspiration 
VAS   Visual analogue scale 
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2. INTRODUCTION 
2.1 The subject of the current thesis 
A pulmonary lesion suspicious of malignancy is a common indication for 
bronchoscopy. The lesions can be visible through the bronchoscope or beyond the 
visual field. Different sampling techniques like biopsy, brushing, needle aspiration, 
and washing are available for the physician. For lesions located beyond the visual 
field, different guidance systems are available to assist in finding the right bronchial 
branches. Virtual navigation from reformatted computed tomography (CT) scans can 
guide a magnetic probe to the lesion. Endobronchial ultrasound (EBUS) with a 
rotating miniprobe can visualise the lesion, when there is contact between the probe 
and the lesion. Use of a guide sheath can lead the sampling devices back to the lesion 
detected by virtual navigation or EBUS. 
Regardless of the use of guidance system, diagnostic yield from a bronchoscopic 
procedure will seldom be one hundred percent, neither in visible lesions nor in lesions 
beyond the visual field. Several factors are likely to influence on the diagnostic yield. 
Combinations of sampling techniques, the size and histology of the lesion, the 
physicians’ level of experience, the selection of the patients, and the follow-up have 
been significant predictors in previous studies (summarised in Table 2). A sufficiently 
long and thorough follow up will be able to detect the false negative cases. The 
diagnostic yield could also depend on the interpretation of the pathological results. 
Cells suspicious of malignancy are likely cancerous, but may lead to a repeat of the 
procedure to attain a definite diagnosis. Previous studies have shown a large variation 
in diagnostic yields. The above-mentioned variables are potentially some of the 
reasons for this variation. The large variation in the results from previous studies 
(Figure 3) illustrates the importance to determine the diagnostic yield and to analyse 
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the predictors in our own centre. This will hopefully lead to improvement of our own 
diagnostic yield and thus improved care, over time.  
The three papers in the current study evaluated different predictors of a higher 
diagnostic yield in bronchoscopy and compared combinations of sampling techniques. 
A retrospective cohort study evaluated the diagnostic yield of bronchoscopy in the 
study centre and detected the main predictors of a higher diagnostic yield. The 
inclusion criteria were wide. The study evaluated the predictors for a higher 
diagnostic yield in bivariate analyses and in multivariate analyses to avoid 
confounding. Due to the retrospective nature of the first study, the choice of sampling 
techniques was exclusively up to the physician performing the procedure. In a 
prospective study, physicians at various levels of experience performed EBUS during 
bronchoscopy on patients with peripheral lesions. 
When the physician is choosing between different combinations of sampling 
techniques, he/she must know something about the increase in the diagnostic yield. 
He/she also needs knowledge about the cost of the different strategies. A cost-
minimisation model was used to analyse the costs of diagnosing visible lesions with 
different sampling techniques. The model included calculated costs in the 
bronchoscopy unit and in the pathological department. The cost of a missed diagnosis, 
the average cost for each sampling technique, and the diagnostic yield of each 
combination of sampling techniques defined the model. The cost-minimisation 
analysis recommended the combination of sampling techniques that had the least 
costly average price that led to diagnosis.  
EBUS with a miniprobe is a possible tool to increase the diagnostic yield in peripheral 
lesions. A prospective open randomised trial evaluated the use of EBUS in our centre. 
All our physicians were trained to control the fluoroscope and to use EBUS with a 
guide sheath. An on-site cytotechnician evaluated the transbronchial fine-needle 
aspiration (TBNA) smears. The study protocol recommended the use of all sampling 
techniques (biopsy, brushing, TBNA, and washing). We assumed a diagnostic yield of 
40 % with fluoroscopy guidance and with all sampling techniques in the non-EBUS 
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group. The diagnostic yield in the EBUS group was predicted to 60 % based on 
previous studies. Standard sample size calculation estimated that 240 patients had to 
be included in the study (=0.05, power=90 %). 
An intention-to-treat analysis evaluated the use of EBUS. A multivariate analysis was 
used to control for potential confounding. A cost-effectiveness analysis evaluated 
different combinations of sampling techniques. The average diagnostic yield for 
benign and malignant disease was the measure of effectiveness. The cost-
effectiveness analysis calculated the incremental cost-effectiveness ratio (ICER) 
based on the increase in cost divided by the increase in effectiveness. ICER 
represented the cost of one additional positive sample. The willingness to pay for one 
additional positive sample was the average calculated cost of a repeated procedure. 
When the ICER for a combination with an additional sampling technique was lower 
than the willingness to pay, the sampling technique was cost-effective. 
The results of the studies presented in this philosophiae doctor (PhD) thesis revealed 
predictors for a higher diagnostic yield. These predictors can guide adjusted or 
stratified analyses in future studies. Further, the current PhD thesis presents the most 
economical combination of sampling techniques in visible and non-visible lesions and 
evaluated EBUS in a real-life setting. 
  
2.2 Historical background 
2.2.1 Bronchoscopy 
Gustav Killian introduced bronchoscopy in Europe when he removed a foreign body 
from the trachea with an oesophagoscope in 1897(1). Killian was known to encourage 
his students to analyse their results(2) and research on this method was thus started. 
The father of bronchoscopy in the United States was Chevalier Jackson. Jackson 
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introduced a bronchoscope with integrated suction in 1904. Still, for both it was a 
challenge to get good illumination of the bronchial tree. Killian used a light bulb 
integrated in the handle of the bronchoscope, with a prism to reflect the light. Jackson 
used distal illumination with a mignon bulb at the tip of the bronchoscope. A major 
leap forward came when Shigeto Ikeda constructed fibreglass illumination for the 
rigid bronchoscope in 1962. The fiberglass illumination contained approximately 
15000 glass fibers with a size less than 15 mm(2). The fibers transported light to the 
distal end of the bronchoscope, and images to the proximal part. Ikeda designed the 
flexible fiberbronchoscope in 1964, and it was commercially available in 1970 from 
Olympus. His paper from 1971 described flexible bronchoscopy with brushing and 
curette biopsy(3). Ikeda further developed the bronchoscope with video technique in 
1983-1987(2). Anderson replaced the surgical biopsy with transbronchial biopsy in 
1963(4). Sackner described bronchoalveolar lavage in 1972(5). TBNA was described 
by Schieppati in 1949(6), but got little attention before Wang reported his results in 
1978(7). 
 
2.2.2 Ultrasound 
The brothers Jaques and Pierre Curie described the ultrasound waves in 1880. They 
found that certain crystals exposed to alternating mechanical stress were excited and 
produced piezoelectricity(8). Piezoelectricity was omitted from the excited crystals as 
waves. After World War II, the knowledge of ultrasound from the Sound Navigation 
and Ranging (SONAR) was explored for medical purposes. The A-mode ultrasonic 
instrument presented blips on an oscilloscope screen. These blips marked the distance 
from the transducer to the lesion. Shigeru Nakajima and Rokuro Uchida built Japan’s 
first A-mode instrument in 1949, simultaneously with John Wild in the United 
States(9). Some of the first reports about the diagnostic value of ultrasound came 
from George Ludwig, United States(10), John Wild, United States(11) and Karl 
Dussik, Austria(12). The compound 2,5 megahertz (MHz) two dimensional B-mode 
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was constructed by Ian Donald in 1957(13). John Wild and John Reid developed a 
small sonographic probe for the rectum in 1957(14). A similar device was used by 
Hürter et al. in the first report about endobronchial ultrasound with a rotating 
miniprobe in the lungs(15). The miniprobe was commercially available in 1999. 
Kurimoto et al. described in 2004 the use of a guide sheath which was guided into the 
correct position with a curette(16). The curette is a bendable device; it can be rotated 
360 degrees, but must be removed before the miniprobe is inserted for identification 
of the lesion. 
 
2.2.3 Lung cancer 
Morgagni reported the first case of lung cancer in 1761(17). The disease was rare 
until the beginning of the nineteenth century. When Adeler published his report in 
1912, he found only 374 published cases with verified lung cancer worldwide(18). 
Lung cancer increased like an epidemic during the 19th century. Doll’s famous report 
about smoking and lung cancer was published in 1950(19), but Lickint from Germany 
assumed the association between lung cancer and smoking already in 1929(20). The 
early German reports have often been ignored, probably because they were associated 
with the Nazi regime(21).  
The age adjusted incidence of lung cancer in Norway was 10.1/100 000 for men and 
2.6/100 000 for women in 1954  The incidence increased to 34.2/100 000 for men and 
24.8/100 000 for women in 2008(22). Lung cancer in Norway increased from average 
285 cases each year in 1954-1958 (220 men and 65 women) to 2529 cases in 2008 
(1422 men and 1107 women). Currently lung cancer has the second highest incidence 
of all cancers for men and the third highest incidence for women in Norway. In 
Norway, 4.4 % of all men and 3.1 % of all women will develop lung cancer by the 
age of 75 years(22).
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Detection of lung cancer 
The radiological evaluation of lesions suspicious of malignancy was initiated by 
Röntgens discovery in 1895(23) making it possible to visualise hyperdense areas of 
the lung parenchyma. The single photon emission computed tomography (SPECT) 
device was invented by David Kuhl in 1964(24). SPECT visualised functional 
information with a gamma camera that detected injected radioactive isotopes. Godfrey 
Hounsfield invented the computed tomography (CT) imaging in 1972(25). CT was 
able to give information about small lesions and provided information about the 
spatial extension of the lesions. Gordon Brownell and Charles Burnham contributed 
to the development of the positron emission tomography (PET) scanner in the 1950’s 
and 1960’s(26). The radiopharmaceutical 2-fluorodeoxy-D-glucose (2FDG) was first 
administrated to humans by Abass Alavi in 1976(27). Ron Nutt and David Townsend 
invented the PET/CT in 2000(28). The PET/CT combines the functional information 
from PET with the detailed anatomical CT picture. It is a sensitive device to detect 
metastases.  
 
Lung cancer management 
Surgery in the lung was first performed by Milton Anthony in 1821(18). The first 
lobectomy for lung cancer was performed by H. Morriston Davies in 1912, but Evarts 
Graham became known as father of lung surgery with his pneumonectomy of lung 
cancer with a surviving patient in 1933(29;30).  
Wilhelm Conrad Röntgen discovered the X-rays in 1895 for which he received the 
Nobel Prize in physics in 1901(23). Emil Grubbe tried to treat breast cancer with 
irradiation the same year(31;32). Tudor Edwards reported a paper in 1946 that 
described insertion of radon seeds through the bronchoscope into the bronchus. The 
radon seeds were left in situ for several days similar to brachytherapy(33). Johnson 
summarised the first randomised studies of irradiation therapy from the 1960’s(34). 
Stereotactic irradiation with high irradiation dose in the tumour and low dose in 
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protected vital organs was available for brain tumours in the early 1980’s(35). 
Stereotactic body radiation therapy for lung cancer was introduced in 1994-
1995(36;37). 
Lois Goodman and Alfred Gilman tried to develop antidotes for the nerve gas 
organophosphates in the early 1940’s when they discovered that nitrogen mustards 
destroyed lymphatic tissue(38-40). Randomised trials of chemotherapy alone or in 
combination with surgery and radiotherapy were initiated in the 1960’s for lung 
cancer(41). Combinations with Cisplatin were introduced in the late 1970’s and are 
still standard therapy. New insight in the mechanisms of cell growth led to targeting 
therapy against tyrosine kinase activity of the epidermal growth factor receptor 
(EGFR) in 2002(42). 
 
2.3 Technical description of the endobronchial ultrasound 
miniprobe 
Ultrasound miniprobes are commercially available from Fujinon and Olympus. The 
Fujinon miniprobes are available in different frequencies (12,15,20,25 MHz) and with 
outer diameter of 1.9-2.6 mm(43). The miniprobes from Olympus are available with 
outer diameter between 1.7 and 2.5 mm (frequencies 12, 20 or 30 MHz)(44). 
Olympus also provides a guide sheath that covers the miniprobe when it is inserted 
into the lesion(45). The guide sheath remains in the lesion when the miniprobe is 
removed, and it can thus guide the insertion of the brush, biopsy equipment or TBNA 
needle(16). Miniprobes from Fujinon and from Olympus have a separate driving unit 
that rotates the whole probe. There is a single transmitter and a single detector in the 
miniprobe. When the transmitter and the detector are rotating, the visual ultrasound 
picture is 360 degrees around the miniprobe. The visual output depends on the 
frequency and the contact with the lesion. It is not possible for ultrasound waves to 
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move through air because of air reflection. When the ultrasound transducer is adjacent 
to solid material, it reveals a picture of the lesion. A low frequency will improve the 
depth of penetration with low resolution. A high frequency probe will have a narrow 
penetration with high resolution. The usual miniprobe has 20MHz frequency with a 
visual output of approximately 4 cm(46).  
Figure 1 (A-C): Ultrasound pictures of air and a malignant lesion 
         
 
 
 
 
1A:Ultrasound picture of air  1B:Ultrasound picture         1C:The miniprobe 
                 of a malignant lesion             
       (within the white borders) 
2.4 The diagnostic approach to visible and peripheral 
lesions  
Table 1 presents a query in PubMed for papers concerning diagnostic bronchoscopy 
published after 1970. There were about 80 publications yearly until 2005, after which 
the publication rate increased to 160 publications yearly. Hürter et al. wrote the first 
publication on endobronchial ultrasound in 1992(15). Most publications analysed 
EBUS-TBNA for lymph nodes, while only approximately 20 % of the 280 EBUS 
publications evaluated the miniprobe for peripheral lesions. 
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Table 1: PubMed search for articles on bronchoscopy and endobronchial 
ultrasound in the diagnosis of lung cancer.  
Year 
Bronchoscopy in 
the diagnosis of 
lung cancer* 
Endobronchial 
ultrasound in the 
diagnosis of lung 
cancer** 
Endobronchial 
ultrasound in the 
diagnosis of 
peripheral lung 
cancer*** 
Before 1970 315   
1970-74 335   
1975-79 297   
1980-84 313   
1985-89 377   
1990-94 385 1 1 
1995-99 482 8 2 
2000-04 631 36 9 
2005-09 797 151 33 
2010 172 84 9 
Sum 4104 280 54 
*PubMed search term: (Diagnosis/Broad[filter]) AND (bronchoscopy) AND (lung cancer)                    
** PubMed search term: (Diagnosis/Broad[filter]) AND (endobronchial ultrasound) AND (lung cancer) 
*** (Diagnosis/Broad[filter]) AND (endobronchial ultrasound) AND (lung cancer) AND (peripheral) 
 
2.4.1 Papers published on bronchoscopy without endobronchial 
ultrasound 
Papers with detection rates for cancer without EBUS are summarised in Table 2. The 
confidence intervals presented in Figure 2 and Figure 3 were calculated based on the 
binominal distributiona. Figure 2 and Figure 3 visualise the spread of reported 
                                              
a
 The standard error (SE) of the detection rate (p) was: Square root (p*(1-p)/n). n: number of cases in the study. The 95 % 
confidence interval was calculated to be from p-1.96*SE(p) to p+1.96*SE(p)(47). 
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detection rates in papers about bronchoscopy for visible and peripheral lesions 
respectively. The papers were identified from Schreiber et al.’s summary of published 
evidence(48), Rivera et al.’s evidence-based clinical practical guideline(49), and a 
PubMed search. Schreiber et al. searched MEDLINE and Cochrane from 1966 to 
2001 for studies that had at least 50 patients with suspected lung cancer. Rivera et al. 
updated the search and included studies up to 2004. The PubMed search included 
studies from 2000 to 2010. (Search term: (Diagnosis/Broad[filter]) AND 
(bronchoscopy) AND (lung cancer) AND (biopsy) AND "2000/01/01"[Publication 
Date] : "2010/12/31"[Publication Date]).  
 
 
Table 2: Published papers with detection rates for cancer in central visible 
lesions and in peripheral lesions 
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1971 Hattori et al.(50)  
1971 Oswald et al.(51) 
1974 Solomon et al.(52) 
1975 Zavala et al.(53) 
1976 Kvale et al.(54) 
1977 Chopra et al.(55) 
1977 Stringfield et al.(56) 
1978 Chaudhary et al.(57) 
1979 Cortese et al.(58) 
1979 Radke et al.(59) 
1981 Buirski et al.(60) 
1981 Ono et al.(61) 
1982 Gellert et al.(62) 
1982 Pilotti et al.(63) 
1982 Popovich et al.(64) 
1982 Wallace et al.(65) 
1983 Lam et al.(66) 
1983 Lundgren et al.(67) 
1983 
 
 
 
 
 
Shure et al.(68) 
1983 Zisholz et al.(69) 
1984 Cox et al.(70) 
1984 Horseley et al.(71) 
1987 Schenk et al.(72) 
1988 Naidich et al.(73) 
1988 Shiner et al.(74) 
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1989 Gay et al.(75) 
1989 Mori et al.(76) 
1989 Wagner et al.(77) 
1990 Mak et al.(78) 
1990 Saita et al.(79) 
1991 Popp et al.(80) 
1991 Buccheri et al.(81)  
1992 Pirozynzki et al.(82) 
1993 de Gracia et al.(83)  
1993 Torrington et al.(84) 
1994 Debeljak et al.(85) 
1994 Milman et al.(86) 
1995 Castella et al.(87) 
1995 Gasparini et al.(88) 
1995 Piaton et al.(89) 
1996 Chechani et al.(90) 
1996 Govert et al.(91) 
1997 Sing et al.(92) 
1998 Aristizabal et al.(93) 
1998 Bilaceroglu et al.(94) 
1998 Mclean et al.(95)  
1998 Wong-surakiat et al.(96) 
1999 Dasgupta et al.(97) 
1999 Govert et al.(98) 
1999 Reichen-berger et al.(99) 
2000 Baaklini et al.(100) 
2000 Bungay et al.(101) 
2000 Diette et al.(102) 
2000 Hsiao et al.(103) 
2000 Lam et al.(66) 
2000 Tang et al.(104) 
2001 Gunen et al.(105) 
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2001 Jones et al.(106) 
2001 Karahalli et al.(107) 
2002 Baba et al.(108) 
2002 Gaber et al.(109) 
2003 Bandoh et al.(110) 
2003 Diaz et al.(111) 
2003 Kawaraya et al.(112) 
2003 
 
Skaansar et al.(113) 
2003 Trkanjec et al.(114) 
2004 Estarriol et al.(115) 
2005 Kaçar et al.(116) 
2005 van der Drift et al.(117) 
2006 Gildea et al.(118) 
2006 Heyer et al.(119) 
2006 Joos et al.(120) 
2006 Schwartz et al.(121) 
2006 Uchida et al.(122) 
2007 Eberhardt et al.(123) 
2007 Lee et al.(124) 
2007 Liam et al.(125) 
2007 Makris et al.(126) 
2007 Shinagawa et al.(127) 
2007 Tachihara et al.(128) 
2007 Tremblay et al.(129) 
2008 Danila et al.(130) 
   34 
2008 Kanemoto et al.(131) 
2008 Oki et al.(132) 
2008 Ost et al.(133) 
2008 Roth et al.(134)  
2009 Roth et al.(135) 
2009 Dobler et al.(136) 
2009 Franke et al.(137) 
2009 Iwano et al.(138) 
2009 Lamprecht et al.(139) 
2010 Aktas et al.(140) 
2010 Boonsarngsuk et al.(141) 
2010 Botana-Rial et al.(142) 
2010 Hautmann et al.(143)  
2010 Schumann et al.(144) 
2010 Seijo et al.(145) 
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Figure 2: Detection rates for cancer in endobronchial visible lesions 
 
 
 
Aktas et al.(140) 
Castella et al.(87) 
Chopra et al.(55) 
Cox et al.(70) 
Dasgupta et al.(97) 
Diaz et al.(111) 
Dobler et al.(136) 
Gaber et al.(109) 
Gellert et al.(62) 
Govert et al.(91) 
Govert et al.(98) 
Gunen et al.(105) 
Horseley et al.(71) 
Hsiao et al.(103) 
Jones et al.(106) 
Kaçar et al.(116) 
Karahalli et al.(107) 
Kvale et al.(54) 
Lam et al.(66) 
Lee et al.(124) 
Liam et al.(125) 
Lundgren et al.(67) 
Mak et al.(78) 
Oswald et al.(51) 
Pilotti et al.(63) 
Popovich et al.(64) 
Popp et al.(80) 
Roth et al.(134)  
Shure et al.(68) 
Sing et al.(92) 
Skaansar et al.(113) 
Solomon et al.(52) 
Stringfield et al.(56) 
Tremblay et al.(129) 
van der Drift et al.(117) 
Zavala et al.(53) 
ZZ         Sum all papers
1,0000,9000,8000,7000,6000,5000,4000,300
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Figure 3: Detection rates for cancer in peripheral lesions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We initiated the work presented in the current PhD thesis in 2005. By then 67 studies 
had reported detection rates for cancer (Table 2). The first studies were descriptions 
of diagnostic yields in endobronchial visible lesions and in peripheral 
lesions(50;51;53). The discussion about the optimal combination of sampling 
Aristizabal et al.(93) 
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Kvale et al.(54) 
Lam et al.(66) 
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Mak et al.(78) 
Makris et al.(126) 
Milman et al.(86) 
Naidich et al.(73) 
Oki et al.(132) 
Oswald et al.(51) 
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Pirozynzki et al.(82) 
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Radke et al.(59) 
Reichen-berger et al.(99) 
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Schwartz et al.(121) 
Seijo et al.(145) 
Shiner et al.(74) 
Sing et al.(92) 
Skaansar et al.(113) 
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van der Drift et al.(117) 
Wong-surakiat et al.(96) 
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ZZ         Sum all papers
1,0000,8000,6000,4000,200
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techniques was introduced by Solomon in 1974(52). Previous papers recommended 
different combinations of sampling techniques: brushing alone(50;52), biopsy 
alone(62;68;86;115), biopsy and sputum(51), biopsy and 
brushing(54;58;59;79;81;85;106), or biopsy, brushing and 
washing(57;65;69;78;100;146). Some studies used a curette with good results 
(53;61;76;110), others recommended to add endobronchial needle aspiration (EBNA) 
for visible lesions or TBNA for peripheral lesions(71;72;75;87;88;90;94;97-
99;107;112).  Bronchoalveolar lavage (BAL) was recommended in some 
papers(66;82;96;104;109;114;147). The papers based the recommendations on the 
diagnostic yields. Many studies were without statistical analyses, some used 
McNemars test for matched pairs. There were no randomised trials. 
When the physician decides the optimal combination of sampling techniques, the 
increase in the diagnostic yield and the increase in cost must be considered. The 
discussion of costs was introduced by Kvale et al. in 1976(54). Kvale et al. 
recommended biopsy and brushing, but not washing. Govert et al. performed a cost-
effectiveness analysis in 1996 (91), but the choice of end-point (quality adjusted days) 
made the analysis hard to interpret. The British Thoracic Society Guidelines on 
Diagnostic Flexible Bronchoscopy recommended biopsy, brushing, and washing in 
2001(148). Rivera et al. recommended addition of TBNA(149). By the initiation of 
the current study there was a need of a analysis for the optimal combination of 
sampling techniques that included costs and effectiveness.  
As previously mentioned, the choice of sampling techniques is only one of the factors 
determining diagnostic yield. Previous studies identified different predictors of a 
higher diagnostic yield. The first studies identified size and endobronchial visibility as 
possible predictors, but no statistical tests were used to confirm the results(50;51;54). 
Stringfield et al. identified size and distance from the main carina as significant 
predictors of a higher diagnostic yield in 1977(56). The predictors of higher 
diagnostic yield identified before the initiation of the current study were: 
size(56;59;60;65;85;86;90;99;100;115), location(56;60;65;80;81;115), endobronchial 
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visibility(80;81;87;95), CT bronchus sign(73;93;94;101;115), and radiographic 
pattern(90;101;147). With so many different bivariate associations, confounding is a 
problem unless a multivariate analysis is performed. The only multivariate analysis 
published before the initiation of the current study was in Diette et al.’s report from 
2000. The report analysed only rapid on-site evaluation (ROSE) of the cyto-
pathological material(102) and was not adjusted for size or endobronchial visibility.  
Figure 2 and Figure 3 displays the diagnostic yields in previous studies for 
endobronchial visible lesions and for peripheral lesions. Some previous studies were 
from selected patients or from highly specialised centres where only a few physicians 
performed the bronchoscopies. There was a need for more studies where all lesions 
suspicious of malignancy were included and investigated by physicians with various 
levels of experience.  
 
2.4.2 Studies of bronchoscopy with EBUS miniprobe 
Table 3 describes the studies of endobronchial ultrasound with a miniprobe for 
peripheral lesions. The studies were identified by a search in PubMed and Embase 
(Search term: (Diagnosis/Broad[filter]) AND (endobronchial ultrasound) AND (lung cancer) AND 
(peripheral)). Steinfort’s metaanalysis(150) and Anantham’s review(151) were searched 
for additional papers. Figure 4 and Figure 5 display the visualisation rates and the 
detection rates for cancer with confidence intervals, stratified by the physicians’ level 
of experience.  
 
Table 3: Visualisation rates and detection rates for peripheral lesions in studies 
with an EBUS miniprobe 
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1992 Hurter et al.(15)  
2002 Herth et al.(152) 
2004 Kikuchi et al.(153) 
2004 Kurimoto et al.(16) 
2004 Shirakawa et al.(154) 
2004 Yang et al.(155) 
2005 Asahina et al.(156) 
2005 Becker et al.(157) 
2005 Paone et al.(158) 
2006 Herth et al.(159) 
2007 Chung et al.(160)  
2007 Dooms et al.(161) 
2007 Eberhardt et al.(162)  
2007 Yamada et al.(163)  
2007 Yoshikawa et al.(164) 
2008 Asano et al.(165)  
2008 Fielding et al.(166) 
2008 Koh et al.(167)  
2009 Eberhardt et al.(168) 
2009 Chao et al.(169) 
2009 Huang et al.(170) 
2009 Oki et al.(171) 
2010 Disayabutr et al.(172) 
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2010 Eberhardt et al.(173)  
2010 Mizugaki et al.(174)  
2011 Roth et al.(175) 
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Figure 4: Visualisation rates with EBUS 
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Figure 5: Detection rates for cancer with EBUS in peripheral lesions 
 
Few studies of EBUS with miniprobe were published before the current study was 
initiated in 2005. In the European Respiratory Society/American Thoracic Society 
(ERS/ATS) statement on interventional bronchoscopy from 2002, Bollinger et al. 
concluded that EBUS was promising, but the diagnostic outcome had to be compared 
in prospective studies(176).  
The main challenges with EBUS in the diagnostic approach of peripheral lesions are 
to visualise the lesion and subsequently to obtain a proper sample from the lesion.  
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1) Visualisation of the lesions 
Hurter et al. visualised 73 % of the lesions in his first report(15). Kikuchi et al. 
reported a high visualisation rate for lesions below 3 cm (79 %)(153). Kurimoto et al. 
visualised 80 % inside the lesion and 13 % adjacent to the lesion(16). Overall the 
visualisation rates in the studies published before 2005 was between 73 % and             
93 %(15;16;152-155).  
 
2) Detection rates for cancer 
Only studies that reported the detection rate for cancer were included in Figure 5. The 
detection rates for cancer in studies before 2005 were 55 % for lesions below 2 
cm(155), 66.7 % for lesions below 3 cm(153) and overall between 66 % and 71 
%(153-155). 
There were few comparative studies between EBUS and conventional sampling 
techniques before 2005. Herth et al. published a randomised crossover study that 
included 50 patients. They performed most of the procedures in general anaesthesia 
with highly trained staff. The procedures were performed with EBUS and without 
EBUS in each patient. The patients were randomised to EBUS first or non-EBUS 
first. The knowledge of the correct position with EBUS could bias the results from the 
non-EBUS group. The diagnostic yield for benign and malignant disease was 76 % 
without EBUS, compared to 80 % with EBUS, but there was a trend for EBUS to be 
superior for lesions smaller than 3 cm(152). Shirakwa et al. compared the results of 
EBUS performed by two physicians to a historical group with patients investigated by 
the same physicians(154). The detection rate for cancer was 71 % with EBUS 
compared to 70 % in the historical control group without EBUS. Yang et al. 
retrospectively compared EBUS to non-EBUS(155). The detection rate for cancer was 
66 % in the EBUS group compared to 43 % in the non-EBUS group (p<0.01). 
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When the current study was initiated, the usefulness of EBUS was unknown in a 
setting where pulmonologists at various levels of experience performed the 
bronchoscopies.  
 
2.5 Evaluation of costs and effectiveness in diagnostic 
approaches 
2.5.1 Cost analyses of strategies 
Several analyses are available to evaluate the costs and the effectiveness of diagnostic 
strategies. The most common analyses are the cost-benefit analysis, the cost-utility 
analysis, the cost-minimisation analysis and the cost-effectiveness analysis(177). The 
cost-benefit analysis measures the cost and the outcome (benefit) in monetary values. 
One type of cost-benefit analysis compares the cost of the strategy to the average 
willingness to pay for the outcome(178). The cost-utility analysis presents the number 
of utility measurement units a strategy can achieve. The most common utility-based 
measurement is the quality adjusted life year (QALY). The cost-utility analysis 
calculates the number of QALY gained by each strategy. Alternative strategies can be 
compared by calculations of cost per QALY(179). The cost-minimisation analysis 
compares the costs of different strategies to a similar outcome(180). All costs of the 
different strategies are calculated and the costs are compared to find the least costly 
strategy. The cost-effectiveness analysis compares the increase in cost with the 
increase in effectiveness. The incremental cost-effectiveness ratio (ICER) gives the 
costs per life year gained, per symptom free day or for an additional positive sample. 
These costs can be compared for different strategies and sensitivity analyses can 
reveal the threshold values for costs and effectiveness measurements(181;182). The 
threshold values are the highest cost or the lowest effectiveness for the strategy to be 
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cost-effective. The willingness to pay decides whether a strategy with higher costs 
and higher effectiveness is cost-effective or not. 
 
2.5.2 Costs 
There are different types of costs: the health service costs, the costs held by the 
patients, and external costs for the society. The health provider’s perspective includes 
only costs for the hospital; the patient’s perspective includes only costs for the patient. 
The recommended perspective is the societal perspective which include all costs for 
the health provider, the patient, and the society(182). The value of the investment and 
the reward will be valued differently at different times. An investment in the future is 
less valued and the value of a future reward is less valued than a present reward. 
Economical analyses discount the monetary value of the costs and the rewards, but the 
discussion about the discount rate is not settled. A range between 3 % and 6 % yearly 
might be appropriate(180;182).  
 
2.5.3 Effectiveness 
In the comparison of different combinations of sampling techniques, the increase in 
the diagnostic yield is easy to interpret. The diagnostic yield can be the effectiveness 
measurement. The incremental cost divided by the incremental effectiveness (ICER) 
will represent the cost of an additional positive sample. Another option is to evaluate 
the average cost to diagnosis for different strategies in a cost-minimisation analysis. 
Two previous studies analysed costs of different combinations of sampling 
techniques. Govert et al. introduced quality reduced days as an effectiveness 
measurement(91). The willingness to pay was calculated to 500$ for avoiding a 
reduced quality of life day in the diagnostic approach. Biopsy and brushing, or biopsy 
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and washing was recommended for endobronchial visible lesions. Sensitivity analyses 
revealed that brushing or washing had to increase the diagnostic yield of 
bronchoscopy with more than 3 % to be cost-effective. Van der Drift et al. analysed 
the addition of brushing and washing to biopsy with simulation of costs. The average 
costs of transthoracic sampling, mediastinoscopy, and thoracotomy were added when 
a diagnostic sampling technique was removed(117). A cost-minimisation analysis 
recommended biopsy with brushing or washing for visible lesions. For non-visible 
lesions, the paper recommended biopsy and washing. Van der Drift et al. stated that 
there was a need for additional studies that compared costs and effectiveness in 
combinations of sampling techniques for visible lesions and peripheral lesions.  
Paper 2 in the current study presented a cost-minimisation analysis for visible lesions. 
The analysis assumed that all lesions were diagnosed within three bronchoscopies. 
The cost-effectiveness analysis in Paper 3 used the diagnostic yield as the 
effectiveness measurement.  
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3. AIMS 
The main aim of the study was to identify weak points in the diagnostic process of 
lung cancer, to improve the diagnostic yield, and to avoid the use of unnecessary 
sampling devices. An effective diagnostic approach will reduce the waiting time for 
the patient and will be cost-effective for the institution. The current study limited the 
evaluation of the diagnostic approach to three aims: 
(1) To evaluate various predictors for a higher diagnostic yield in bronchoscopy.  
(2) To evaluate different combinations of sampling techniques in bronchoscopy of 
endobronchial visible lesions and peripheral lesions not visible by bronchoscopy.  
(3) To evaluate endobronchial ultrasound (EBUS) with a rotating miniprobe for 
peripheral lesions in a real-life situation among pulmonologists at various levels of 
expertise.   
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4. MATERIAL AND METHODS 
The retrospective cohort study evaluated different predictors of the diagnostic yield in 
bronchoscopy, and compared different combinations of sampling techniques for 
visible lesions. The prospective open randomised trial evaluated the effectiveness of 
endobronchial ultrasound for peripheral lung lesions, and compared different 
combinations of sampling techniques for peripheral lesions in a cost-effectiveness 
analysis. 
 
4.1 Study design for the retrospective study 
Kjetil Roth (KR) and Tomas Mikal Eagan (TME) read the bronchoscopy reports and 
registered the indications and the findings in all 1438 bronchoscopies performed in 
2003 and 2004 at Haukeland University Hospital. The follow-up included 493 
patients with lesions suspicious of malignancy and lasted to November 2005. Of the 
493 patients, 367 had malignant disease. We excluded four patients without any 
samplings. Thus, 363 patients remained in the final analysis presented in Paper 1.  
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Figure 6: Flow chart for Paper 1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Paper 1 was restricted to those with a lesion suspicious of malignancy as an indication 
for bronchoscopy. Patients examined with indications haemoptysis, atelectasis or 
pleural disease were not included in Paper 1. Paper 2 included all patients among the 
1438 bronchoscopies from 2003 to 2004 that had visible lesions. The malignant and 
the benign lesions were included in the cost-minimisation analysis in Paper 2.  
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Figure 7: Flow chart for Paper 2: 
 
 
 
 
 
 
 
 
 
 
 
4.2 Methods for the retrospective study 
The bronchoscopies were performed with Olympus BF 1T 160 bronchoscopes, using 
Boston “Radial Jaw 3” for biopsies, Boston 21 gauche “stifcor” or “eXcelon” needles 
for EBNA/TBNA, and Boston “Cellebrity” for brushings. Patients were semi-sedated 
with pethidine hydrochloride 25-75 mg or midazolam 2.5-5 mg. The physicians used 
fluoroscopy guidance in some of the samplings (48/131or 36.6 %). Twenty-three 
medical doctors performed the procedures without the help of an on-site 
cytotechnician. The washing was an aspiration of a sample from the fluid obtained 
during the whole procedure.  
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4.3 Data collection in the retrospective study 
An electronic search for procedure codes and a manual search in the planning registry 
for all bronchoscopies performed, detected all bronchoscopies done from 2003 to 
2004. The indication for bronchoscopy, the endobronchial findings and the 
complications was obtained from the bronchoscopy reports. Friedemann Leh (FL) 
provided the results from the pathological department electronically in systemised 
nomenclature of medicine (SNOMED) codes. KR and TME retrospectively reviewed 
the CT scans and the chest radiographs of the patients included in the study; and 
registered the size and the location of the lesions. To assure that all patients with 
malignant disease were included in the study, KR reviewed SNOMED codes from the 
pathological department, the electronically obtained mortality data and all future 
medical record diagnoses until November 2005. Patients discharged with a lesion 
suspicious of malignancy were followed manually by repeated searches in the patient 
medical records until November 2005.  
 
4.4 Processing the data file in the retrospective study 
4.4.1 Inconsistencies 
KR compared the codes from the patient medical records to the SNOMED codes, any 
inconsistencies were looked up manually in medical records. The size of the lesions 
was within the possible range. If the nurse registered that a procedure like biopsy, 
brushing or TBNA was performed, but no SNOMED code was available, the 
procedure was regarded as not performed.  
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Merging errors could occur when the data from the SNOMED registry was merged 
with the data set. All SNOMED codes obtained were controlled by the diagnosis 
registry and in patient medical records to avoid merging error.  
 
4.4.2 Missing values 
The physicians registered the localisations of the lesions based on the appearance in 
the CT scan. It was not possible to determine the location in 12 cases. Also, three 
additional cases had lesions on both sides and thus 15 cases had indeterminate 
location data. The distance from the lesion to the carina was the distance between the 
carina and the proximal border of the lesion on the chest radiograph. For the patients 
without chest radiographs before the procedure, the physicians measured the distance 
on the scout from the CT scan. It was not possible to measure the distance to carina in 
40 patients. In four patients with chest radiographs, it was impossible to see the lesion 
or to determine the edge of the lesion. In 36 patients without chest radiographs it was 
impossible to get a CT scout or to use the scout to determine the distance from carina. 
Both the variables distance to carina and location were included in the multivariate 
analysis with indeterminate as separate entities.  
All sampling techniques (biopsy, brushing, TBNA, and washings) were performed in 
only 38 cases with visible lesions, 21 cases with compression of a visible bronchus or 
impression of the lesion into the bronchus, and 4 cases with non-visible lesions. The 
evaluation of combinations of sampling techniques was restricted to pairs of sampling 
techniques. For visible lesions, biopsy and EBNA (n=86), biopsy and brushing 
(n=46), and EBNA and brushing (n=47) were evaluated. For non-visible lesions 
biopsy and TBNA (n=48), biopsy and brushing (n=42), and TBNA and brushing 
(n=51) were evaluated. 162 patients were included in the cost-minimisation analysis 
in Paper 2. 127 were biopsied, 50 underwent biopsy and brushing, and 41 biopsy, 
brushing, EBNA, and washing. 
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4.4.3 Variables 
Paper 1 
The main outcome variable was the detection rate of cancer in the first bronchoscopy. 
Some patients had multiple bronchoscopies, but only the first bronchoscopy was 
included in the analysis. The dichotomous outcome variable was positive for a final 
diagnosis obtained by the first bronchoscopy, and negative for negative or uncertain 
results from the pathological department. The evaluated predictors for a higher 
diagnostic yield were distance from carina, localisation, size, and endobronchial 
visibility. The multivariate analysis included age and gender. Age was categorised in 
four quartiles. Distance from carina, age, and size were categorised to make the 
interpretation easier. The size of the lesions was divided into categories resembling 
Chechani’s report from 1996(90). The categories were reduced to only four: I: <2cm, 
II: 2-3cm, III: 3-4cm, and IV: >4cm. The distance from the carina of 5 cm 
approximately divided the data set in two. Location was divided into categories by 
side and by lobe. Mediastinum was treated as a separate entity apart from the lobes. 
The cases with indeterminate data were treated as separate entities. 
 
Paper 2 
The costs of the different sampling techniques were estimated in Norwegian kroner 
(NOK) 2007-value and adjusted to 2004-value with the consumer price index for 
Norway. The costs were then recalculated to euro, to be comparable to other 
countries. The time consumption of the workers in the bronchoscopy lab and in the 
department of pathology were estimated based on 24 bronchoscopies registered in 
detail, 25 registries from the pathologist, and 11 registries from the cytotechnicians. 
Staff in the department of pathology provided expert opinions for some of the time 
estimations. (Appendix A1 describes the calculation of costs.)  
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The diagnostic yield for each combination of sampling techniques was the combined 
diagnostic yield for malignant and benign lesions (average detection rate for cancer 
and the average ability to give a definite result for benign lesions in the initial 
bronchoscopy). The cost-minimisation analysis assumed that the diagnostic yields for 
visible lesions were similar in the first, the second, and the third bronchoscopy. The 
cost-minimisation model assumed that bronchoscopy secured a diagnosis for visible 
lesions within three bronchoscopies. A model with different strategies to a final 
diagnosis was built based upon the diagnostic yield of the different combinations of 
sampling techniques. The least costly strategy was preferred.  
 
4.4.4 Statistical analyses 
Paper 1 
Chi-square tests were used to analyse the bivariate relations between the different 
predictors and the detection rates for cancer. A p-value below 0.05 was considered 
significant. The Chi-square test is valid for independent samples; it compares the 
actual distributions to expected distributions. All (observed-expected)2/expected are 
summarised and compared to a Chi-square distribution for the actual degrees of 
freedom. The p-value represents the probability for the actual distribution to happen 
by chance.  
A multivariate logistic regression analysis was performed to detect confounding. In 
the logistic regression model the probability for a positive diagnosis (y=1) is defined 
by a constant () and the effect of a variable (x). p(y=1)=(e+x/(1+ e+x). Multiple 
variables can be evaluated: p(y=1)=(e+ 1x1+2x2+3x3… /(1+ e+ 1x1+2x2+3x3…) where 
1x1 represents the first variable 2x2 the second etc. The predictors are significant 
when the confidence interval for e does not include 1.  
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McNemars test was used to compare different combinations of sampling techniques. 
McNemars test of A and B compares the number of cases with A+B- to the number of 
cases with A-B+. All statistical analyses in Paper 1 were performed in SPSS(183). 
 
Paper 2 
The cost-minimisation analysis was performed in TreeAgePro Healthcare(184). We 
constructed a decision model based on the diagnostic yield of different combinations 
of sampling techniques and on the estimated cost for each sampling technique. Only 
visible lesions were included. We assumed that bronchoscopy secured a diagnosis for 
all visible lesions within three bronchoscopies. A comparison of costs and diagnostic 
yields calculated the least costly way to a final diagnosis. Sensitivity analyses were 
used to compare the costs and the diagnostic yields in the different strategies. The 
costs and the diagnostic yields were increased and decreased to reveal the threshold 
values for the least costly strategy.   
 
4.5 Approvals for the retrospective study 
The Regional Norwegian Ethical Committee (008.05) and the Norwegian Social 
Science Data Service (12244) approved the retrospective study.  
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4.6 Study design for the prospective study: study sample 
The prospective study was an open randomised trial. The sample size was calculated 
to 120 patients in both study arms based on a predicted  rise in the diagnostic yield 
from 40 % in the non-EBUS group to 60 % in the EBUS group (standard sample size 
calculation, =0.05, power: 90 %). The predicted diagnostic yields were based on 
preliminary results of bronchoscopy with fluoroscopy in the retrospective study(134) 
for the non-EBUS group, and on previous studies for the EBUS 
group(16;152;154;155;164). The inclusion started in June 2005 at the Department of 
Thoracic Medicine, Haukeland University Hospital, Bergen. In October 2006 Ålesund 
hospital was included as the second centre. There were 289 patients when the 
inclusion closed in January 2009. The bronchoscopies revealed 25 patients with 
unsuspected visible endobronchial lesions, thus 264 patients remained in the study 
population. Based on a quality registry for all bronchoscopies in the study period, it 
was possible to identify 130 additional patients that could have been included in the 
study. These patients had lesions suspicious of malignancy on the CT scan and the 
bronchoscopy registry reported no visible lesions. The main reasons for non-inclusion 
were periods with equipment failure, patients not willing to participate, and an 
incorrect assumption that there was an endobronchial visible lesion based on the CT 
scan. 
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Figure 8: Consort flow diagram for the prospective study: 
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4.7 Methods for the prospective study 
Twenty-nine physicians performed the procedures transorally with Olympus BF 1T 
160 bronchoscopes. The patients were semi-sedated with pethidine hydrochloride 25-
75 mg or midazolam 2.5-5 mg. After reviewing the study information with the 
potential subject and obtaining informed consent, the physicians opened an envelope 
revealing randomisation to EBUS or non-EBUS before the bronchoscopy. Prior to the 
procedure, the physicians identified the optimal segment for sampling by CT scans in 
both the EBUS group and in the non-EBUS group.  After initial inspection of the 
central airways, the physicians excluded patients with endobronchial visible lesions. 
Fluoroscopy guided the TBNA, biopsy, and brushing towards the lesion in the non-
EBUS group and guided the EBUS probe towards the lesion in the EBUS group.  
The EBUS miniprobe was an Olympus 20 MHz 1.7 mm rotating probe with guide 
sheath. It was marked with cellulose tape proximally to the guide sheath before the 
bronchoscopy. The cellulose tape marked the position when the ultrasound transducer 
was just outside the guide sheath orifice. (Figure 9)(16).  
 
Figure 9: The EBUS miniprobe in the guide sheath 
 
The TBNA needle, the brush and the biopsy forceps were also marked with cellulose 
tape before the bronchoscopy. The TBNA and the brush were marked with the tip of 
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the needle sheath or the brush sheath adjacent to the guide sheath orifice. The 
cellulose tape marked the position where it was possible to open the biopsy forceps 
just outside the guide sheath (Figure 10).  
 
Figure 10: The optimal position for the cellulose plaster on TBNA, brushing, 
and biopsy 
 
The upper picture displays the retracted position of the device, the lower picture the pulled out or opened 
position of TBNA, brushing and biopsy. 
 
The miniprobe with a guide sheath was directed towards the lesion guided by 
fluoroscopy. Only air reflection was seen until contact between the ultrasound 
miniprobe and the lesion. If the EBUS signal indicated that the probe was inside the 
lesion, the miniprobe was removed and the samples were taken through the guide 
sheath as described by Kurimoto(16). A small metal marker on the guide sheath was 
visible by fluoroscopy to verify the stable correct position of the guide sheath (Figure 
9). The guide sheath remained in position just in front of the lesion (Figure 11). 
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Figure 11: The optimal position of the guide sheath adjacent to the lesion 
  
The ultrasound miniprobe is retracted from the lesion. The guide sheath is left just in front of the lesion. The 
sampling device is guided into the lesion by the guide sheath. 
 
In difficult cases the miniprobe was removed from the guide sheath and a curette was 
inserted in order to guide the sheath into the lesion (Figure 12)(153). 
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Figure 12: A curette can lead the guide sheath into the optimal bronchial 
branch 
 
 
Rapid on-site evaluation (ROCE) was available for both groups. The sampling was 
initiated with two TBNA punctures of the lesions. While the cytotechnicians 
evaluated the TBNA smears directly in the bronchoscopy lab, the physicians took four 
biopsies. If the smears were representative, the physicians concluded the investigation 
with brushing and small volume lavage. He/she repeated the TBNA if the 
cytotechnicians found the smears to be non-representative. Biopsies and small volume 
lavage (SVL: 10-20 ml saline was flushed into the actual bronchial branch) were 
fixed in formalin. TBNA and brushings were fixed in alcohol on a glass slide. In 
addition, a sample of 10–20 ml aspirated from the suctioned rinsing during the entire 
bronchoscopy procedure was fixated in formalin. Two hours after the bronchoscopy 
the patients filled out a form with a visual analogue scale (VAS) where zero was no 
discomfort and 10 extremely high grade of discomfort during the procedure. 
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4.8 Data collection in the prospective study 
KR performed a simple randomisation without stratification in the computer 
programme Microsoft Excel. A physician informed the patient about the procedure 
and asked if the patient would participate in the study. The patient filled in an 
informed consent form. The physician opened a sealed envelope before the 
bronchoscopy, with randomisation to EBUS or non-EBUS and excluded patients with 
visible endobronchial lesion. The physician registered electronically the findings 
during bronchoscopy for the included patients. He/she measured the sizes and 
registered the locations based on the CT scans. Whether the lesion was visualised by 
EBUS or reached by fluoroscopy were registered. KR followed all patients with a 
non-malignant bronchoscopy conclusion until September 2009 unless operation or 
autopsy confirmed a malignant diagnosis prior to this. The patients were followed by 
searches in the patient medical records and by chest radiograph and CT scan 
descriptions. The final diagnosis was obtained electronically from the SNOMED 
registry. The diagnosis from the SNOMED code was controlled by diagnoses from 
the patients medical records and diagnoses in the death registry. A quality registry 
detected the non-included patients.  
 
4.9 Processing the data file in the prospective study 
4.9.1 Inconsistencies 
Some reports had inconsistencies between randomisation and EBUS performance. KR 
controlled these by a manual search in the patient medical records and in the 
randomisation sheet. Cases with registered EBUS and randomisation to non-EBUS 
were typing errors. If EBUS not was performed in the EBUS group, KR controlled 
that the information was true. The codes from the medical records controlled the 
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SNOMED codes. KR controlled all the final SNOMED codes for each patient with 
manual searches in the patients’ medical records. The size of the lesions was within 
the possible range. 
 
4.9.2 Typing errors 
Typing errors could occur in the data obtained from the physician who performed the 
bronchoscopy. Typing errors of size and location were possible, but the lesions were 
within a reasonable range. KR categorised the difficulty to reach the target based on 
the CT scans. This categorisation was not controlled.  
Merging errors could occur when the nurse registry was combined with the data filled 
in by the physicians and when the SNOMED codes were merged into the data set. KR 
controlled that the SNOMED codes for each sampling technique were from the same 
date and the same location. The results were confirmed in the diagnosis registry and 
by manual follow up in the patient medical records. 
 
4.9.3 Missing values 
Though EBUS was not performed in 7 of 124 patients in the EBUS group, these 
seven cases were included in the intention-to-treat analysis. KR registered the size and 
the location retrospectively when there was missing data. There were no missing 
values for baseline characteristics, final diagnoses, or for the predictors of a higher 
detection rate for cancer. It was not possible to perform biopsy, brushing, TBNA, and 
washing in all cases. The cost-effectiveness analysis included 178 patients with all 
sampling techniques performed. The physicians used fluoroscopy in 121 of 124 
procedures (98 %) in the EBUS group, 137/140 (98 %) in the non-EBUS group. The 
procedure time was registered in all cases, but because the SPSS data entry 
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station(185) made a new file when the programme abruptly was ended, some data 
were lost and the procedure time was available for only 221 of  264 cases. 175 of 264 
patients completed discomfort forms. 
 
4.9.4 Variables 
The main outcome variable was the diagnostic yield in peripheral lesions stratified by 
EBUS. The main analyses of sensitivity, specificity, positive predictive value and 
negative predictive value included both the malignant and the benign cases. The 
subgroup analyses and the multivariate analysis included only the cases with 
malignant disease. Size, endobronchial difficulty, endobronchial visibility, and 
location were possible predictors for a higher diagnostic yield. Gender and age were 
not included in the multivariate analysis because there were no significant 
associations with the outcome. Based on previous randomised studies of 
endobronchial ultrasound, size was divided into lesions above 3cm and lesions below 
3 cm(152;158). KR reviewed all CT scans and classified the endobronchial difficulty 
grade. Endobronchial difficulty was divided into four categories based on previous 
reports of the CT bronchus sign(93;94) and comparable to Yoshikawa’s three 
categories(164). The four categories were: I) A bronchial branch straight to the lesion. 
II) No direct path to the lesion, but one or two divisions to pass beyond the visible 
divisions. III) No direct path to the lesion, but three or more divisions to pass beyond 
the visible divisions. IV) No bronchial branch leading to the lesion.  The physicians 
excluded patients with endobronchial lesions, but they did not exclude patients with 
endobronchial constriction or compression. Endobronchial visibility adjusted the 
analysis to avoid confounding from constriction and compression. Location was 
analysed by lobe.  
The costs of the sampling techniques were from the values presented in Paper 2, 
adjusted to euro 2007 value. The willingness to pay for one additional positive sample 
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was 2800 euro based on the cost of one additional bronchoscopy and the cost of five 
days in a day ward. The day ward cost was the diagnosis related group (DRG) cost. 
The willingness to pay for one additional positive sample represented the average cost 
of a repeated investigation.  
 
4.9.5 Statistical analyses 
The bivariate analyses were performed with Chi-square tests when the expected 
counts in all cells were above 5. The Fisher’s exact test was performed when the 
expected count was below 5. A multivariate logistic regression evaluated the results 
to avoid confounding and to display interactions. The statistical analyses were 
performed in SPSS(183) and the interaction was analysed in STATA(186). 
The cost-effectiveness analysis was performed in TreeAgePro Healthcare(184). The 
main outcome was defined as the combined diagnostic yield for malignant and benign 
lesions in the initial bronchoscopy. All equipment costs and the personnel costs in the 
bronchoscopy unit and the pathological department were included and ICER was 
calculated. ICER is the increase in cost divided by the increase in effectiveness. It 
represents the cost of one additional positive sample. The willingness to pay for one 
additional positive sample was the average cost for an additional diagnostic 
procedure. The cost-effectiveness analysis compared different strategies with addition 
of other sampling techniques to biopsy. Each addition was cost-effective when the 
ICER was below the willingness to pay. Sensitivity analyses for costs and detection 
rates for cancer revealed the threshold values for each strategy to be cost-effective.      
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4.10 Approvals for the prospective study 
The Regional Norwegian Ethical Committee (008.05) and the Norwegian Social 
Science Data Service (12244) approved the retrospective study.  
The Regional Norwegian Ethical Committee (69.05) and the Norwegian Social 
Science Data Service (12562) approved the prospective study. The prospective study 
had ClinicalTrials.gov number NCT00398970. 
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5. SYNOPSIS OF PAPERS 
The results of these studies are presented in three papers, each published in 
international peer-review journals:  
 
5.1 Paper 1 
Roth, K., Hardie, J. A., Andreassen, A. H., Leh, F., and Eagan, T. M. L. Predictors of 
Diagnostic Yield in Bronchoscopy: a Retrospective Cohort Study Comparing 
Different Combinations of Sampling Techniques. BMC Pulmonary medicine 26-1-
2010;8(2). 
Bronchoscopy is the main diagnostic method in the diagnostic approach for lesions 
suspicious of malignancy in the lung. The predictors of a higher diagnostic yield can 
demonstrate the main challenges in the diagnostic process and guide the choice of 
sampling techniques. It is important to be aware of these predictors in the evaluation 
of studies of bronchoscopy. 
The objective of the first paper was to identify the main predictors for a higher 
diagnostic yield in bronchoscopy and to compare the diagnostic yield in different 
combinations of sampling techniques.  
The detection rate for cancer was 17 % in lesions not visible by bronchoscopy, 34 % 
when bronchoscopy revealed constriction or compression from the lesion, and 77 % 
in procedures with endobronchial visible lesions. Gender, age, size of the lesion, 
distance from carina, endobronchial visibility, and location (lobe) were analysed as 
possible predictors for a higher diagnostic yield. Endobronchial visibility, size, and 
distance from carina were significant in bivariate analyses, but only size and 
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endobronchial visibility remained significant in the multivariate analysis. Biopsy and 
TBNA had the highest diagnostic yield among pairs of sampling techniques in visible 
and non-visible lesions. The combined diagnostic yield for biopsy and TBNA was 
significantly higher than the diagnostic yield for each sampling technique alone.  
 
5.2 Paper 2 
Roth, K., Hardie, J. A., Andreassen, A. H., Leh, F., and Eagan, T. M. L. Cost 
Minimization Analysis for Combinations of Sampling Techniques in Bronchoscopy 
of Endobronchial Lesions. Respiratory Medicine 2009;103(6):888-94. 
A comparison of different sampling techniques should simultaneously evaluate both 
costs and the diagnostic yields. The objective of the second paper was to find the least 
costly strategy for obtaining the final diagnosis of endobronchial visible lesions.  
The cost of each sampling technique included the costs in the bronchoscopy unit and 
the costs in the department of pathology. The equipment costs and the average time 
consumptions for the different groups of employees were calculated. The model 
assumed that the diagnostic yield in the second and the third bronchoscopy was 
similar to the diagnostic yield in the first bronchoscopy and that bronchoscopy 
secured a diagnosis for all cases within three bronchoscopies. The diagnostic yield for 
benign and malignant disease increased from 76 % for biopsy alone to 79 % for 
biopsy and brushing. Biopsy, brushing, and EBNA had a diagnostic yield of 86 %, 
washing did not increase the diagnostic yield. The cost-minimisation analysis revealed 
biopsy, brushing and EBNA as the least costly strategy for attaining the final 
diagnosis. Biopsy and brushing was less costly than biopsy alone when brushing 
increased the diagnostic yield with 2 % and the cost of brushing was below 83 euro. 
The combination of biopsy, brushing, and EBNA was less costly than biopsy and 
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brushing when EBNA increased the diagnostic yield with 5 % and the cost of EBNA 
was below 205 euro. 
 
5.3 Paper 3 
Roth, K., Eagan, T. M. L., Andreassen, A. H., Leh, F., and. Hardie, J. A.  A 
Randomised trial of Endobronchial Ultrasound guided sampling in Peripheral Lung 
Lesions. Lung Cancer  2011 (In Press);doi:10.1016/j.lungcan.2011.02.013 
Endobronchial ultrasound with a guide sheath is a possible tool to increase the 
diagnostic yield in bronchoscopy of peripheral lung lesions. When the ultrasound 
transducer is inside the lesion, the ultrasound picture verifies the position. The guide 
sheath can direct the various sampling techniques into the lesion.  
The objective of the third paper was to evaluate endobronchial ultrasound for 
localising and sampling peripheral lung lesions in a setting with multiple physicians at 
various levels of experience. A cost-effectiveness analysis evaluated different 
combinations of sampling techniques in peripheral lesions.  
The sensitivity for cancer was 36 % in the EBUS group and 44 % in the non-EBUS 
group (not significant (NS)). Size and endobronchial difficulty were significant 
predictors for a higher diagnostic yield. In the multivariate analysis there was an 
interaction between the use of EBUS and lesion size; lesions smaller than 3 cm had a 
significantly lower diagnostic yield in the EBUS group compared to the non-EBUS 
group. 
The detection rate for cancer increased from 37 % for biopsy alone to 44 % for biopsy 
and brushing. The cost increased from 50 euro for biopsy alone to 112 euro for biopsy 
and brushing. ICER for biopsy and brushing was 1211 euro compared to biopsy 
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alone. This was below the willingness to pay for one additional positive sample (2800 
euro). Additional washing or TBNA had ICER of 4761 euro for biopsy, brushing, and 
washing and 8262 euro for biopsy, brushing, washing, and TBNA. Both were above 
the willingness to pay. Biopsy and brushing was the most cost-effective combination 
of sampling techniques for peripheral lesions when brushing increased the diagnostic 
yield with minimum 3 % and the cost of brushing was below 142 euro.  
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6. DISCUSSION 
6.1 Discussion of the methods 
6.1.1 Study design 
A retrospective cohort study analysed different predictors of the diagnostic yield and 
evaluated different combinations of sampling techniques for endobronchial visible 
lesions. A prospective randomised trial evaluated endobronchial ultrasound with a 
miniprobe and different combinations of sampling techniques for peripheral lesions. 
Generally, a retrospective study is least costly, allows inclusion of all patients, can 
detect associations between variables, but cannot prove causal relationships between 
exposure and outcome. Only predictors available before the choice of sampling 
technique were included in the analysis. Sex, age, size, and location based on the CT 
results were available before the bronchoscopy. The physician was aware of the 
endobronchial visibility before the sampling started, thus the analysis included 
endobronchial visibility as a potential predictor. The histological result was not 
available before the bronchoscopy. 
The main weakness of the retrospective design is the lack of standardisation. The 
physicians performed the procedures without a protocol. The appearance of the 
lesions on CT thorax probably influenced the choice of sampling techniques and the 
use of fluoroscopy. The physicians applied all sampling techniques in only few cases. 
There was a possibility for a selection bias in the evaluation of sampling techniques. 
A randomised controlled trial evaluates the effect of the different randomised 
modalities on an outcome. The confounding factors will have a similar distribution in 
the exposed and non-exposed cases, thus there should be no net effect of the various 
confounding factors. A double blind controlled randomised trial also has the 
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possibility to eliminate confounding effects of the physician’s or the patient’s 
awareness of the modality choice. In an open prospective trial, the choice of modality 
is random, but physicians and patients will be aware of the assigned groups. A 
weakness of the prospective trial is the effect of non-inclusion. If the non-inclusion is 
random, the results are valid. If selection is limited to a restricted group, the result 
will be valid only for groups with similar limitations. The two main weaknesses of the 
current prospective trial were the effect of the learning curve and the effect of non-
inclusion. The introduction of new modalities will have a learning curve where the 
diagnostic yield gradually increases. The aim of the study was to evaluate 
endobronchial ultrasound in a setting where several physicians at various levels of 
experience performed the bronchoscopies. The high number of physicians who 
participated resulted in only a few included cases for each physician. The results 
might have been different with a higher level of experience. The non-inclusion might 
have introduced selection bias. The results might have been different with another 
selection.     
 
6.1.2 Validity 
Validity of a test is the test results compared to a gold standard. Büttner defined 
validity as the ability of a diagnostic measure to answer a medical question 
correctly(187). Sensitivity and specificity compare the test results to a gold standard. 
Sensitivity is the tests ability to detect positive cases; specificity is the tests ability to 
score negative cases as negative. The test results will depend on the definition of the 
gold standard. If only cases with a final pathological malignant diagnosis are included 
in the gold standard, all cases with clinically defined malignant disease will be 
excluded. Cases with clinically proven cancer will always have a negative 
bronchoscopy and the diagnostic yield will be higher if these cases were excluded. If 
clinically defined malignant disease and malignant disease without reconfirmation are 
included in the gold standard, these cases will be more prone to false positivity than 
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the cases with malignant disease confirmed by CT-biopsy, operation or autopsy. The 
current study tried to reflect a real-life situation. All cases without a confirmed 
malignant diagnosis were followed clinically. Clinically proven lung cancer was 
included in the gold standard.  
Reliability is the stability of the test. The stability is measured by test-retest reliability, 
internal consistency or interrater reliability(188). Test-retest reliability measures the 
ability to give the same result in a repeated test in the same patient. Internal 
consistency is the ability to get the same result in equivalent patients. Interrater 
reliability measures the tests ability to get the same result with different observers. It 
was not considered ethically acceptable to perform repeated bronchoscopies on the 
patients to measure the reliability of the bronchoscopy results.  
 
6.1.3 Internal validity 
The internal validity describes the influence of bias and confounding on the results in 
the study population. Selection into the study or the information given by the patient 
are possible systematic errors or biases. Systematic errors and confounding can 
interfere with the results of the study.  
Selection bias  
Selection bias appears when the selection process disturbs the study results. In the 
retrospective study, the physician who performed the bronchoscopy decided on the 
use of sampling techniques. In very difficult cases, the physician might have chosen 
washing alone. The comparison of different sampling techniques was probably valid 
for cases with those sampling techniques performed, but there was a possibility that 
cases without the actual sampling techniques were different. Even in the prospective 
study, it was not possible to perform all sampling techniques in every case (all 
sampling techniques were performed in 178 of 264 cases). The results of the 
comparison between the techniques might be prone to selection bias. Brushing 
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increased the diagnostic yield with 9 % (from 64 % to 73 %) in cases with a bronchial 
branch going directly towards the lesion. The increase was 7 % (from 33 % to 40 %) 
in cases with one or two bronchial divisions to pass before reaching the lesion, and    
5 % (from 23 to 28 %) in cases with three or more bronchial branches to pass before 
the target lesion. The cases with no bronchial branch to the lesion had no increase in 
the diagnostic yield with brushing. This exemplifies that a selection of patients based 
on endobronchial difficulty might influence the choice of sampling techniques.  
The predictors for a higher diagnostic yield (size and endobronchial visibility) in the 
retrospective study were unlikely affected by selection bias. There might have been 
some missing cases due to wrong identification from the patient medical records, but 
a systematically selection bias was unlikely.  
Non-inclusion in the prospective study was a possibility for selection bias as we later 
identified 130 additional patients that should have been included in the study. Table 4 
compares the non-included patients to the patients in the study. There was a 
significant higher rate of men in the study population and a trend for more lesions in 
the upper lobe for the non-included cases. Reluctance of women to participate in 
randomised studies might be an explanation for the difference in gender. Location and 
gender were not significant predictors of the diagnostic yield in the study. A 
difference in size between the groups was expected if the physicians were reluctant to 
include the difficult cases. There were no differences in size between the included and 
the non-included cases.  
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Table 4: Comparison of the included and the non-included cases  
 Included in  
the study 
Not included 
in the study 
p 
Sex   <0.01 
Male 64 % 51 %  
Female 36 % 49 %  
Lobe   0.06 
Upper lobe 53 % 63 %  
Middle lobe/Lingula 14 % 6 %  
Lower lobe 34 % 32 %  
Size   0.12 
<2cm 27 % 20 %  
2-3cm 18 % 28 %  
3-4cm 18 % 19 %  
>4cm 37 % 33 %  
It seems unlikely that the difference in gender influenced the results, but selection 
bias from other unknown factors cannot be ruled out. The similar distribution of size 
among the included and the non-included cases suggests that the effect of selection 
bias was probably small.  
Information bias 
Information bias can occur when there is a systematic error in the information given 
by patients or the health providers. The most common information bias is recall bias. 
Sick patients remember more than healthy patients do. In an open randomised study, 
the investigator can register different information from a procedure with intervention, 
than from a procedure without an intervention because he or she is prejudiced about 
the intervention.  
The information in the retrospective study was from the physicians’ registrations in 
the patients medical records. The investigator who registered the medical records was 
blinded for the final diagnosis of the patient at the time when he registered the 
findings. In the prospective randomised trial, the physicians performing the 
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bronchoscopies registered the findings. The randomisation was open, but the 
physician was not aware of the final diagnosis when he/she registered the 
information. Only the registration of the size of the lesions was prone to information 
bias due to the open randomisation. The pathologists were not aware of the 
randomisation when the diagnoses were reported. KR classified endobronchial 
difficulty blinded for the randomisation.  
Confounding 
Confounding is when other factors, known or unknown, influence on the measured 
association between an exposure of interest and a given outcome. The confounding 
factors are extraneous to the suggested pathway(189). Confounding can disturb the 
results of a cohort study. Randomisation effectively excludes confounding if the 
distribution of the confounding factors is even among different groups. Thus, the 
evaluation of EBUS was probably not confounded, but the analysis of different 
predictors for a higher diagnostic yield might have been confounded in the 
retrospective or in the prospective study. The current studies did not include histology 
as a possible predictor of the diagnostic yield, though some previous studies 
have(59;66;69;92;96;108;111;124). The physician is not aware of the tumour 
histology when he/she chooses the guidance methods or the sampling techniques for 
the bronchoscopy procedure. The difference in endobronchial visibility of different 
cancer types might have confounded the results of histology being a predictor in 
previous studies. Sing et al found a central location for small cell lung cancer in 17/23 
(74 %) and for adenocarcinoma in 25/64 (39 %)(92).  
To minimise confounding, the current study presented bivariate analyses and 
multivariate analyses. The bivariate analyses revealed whether the association 
between the predictor and the outcome was significant or not. To consider the 
confounding effect and to adjust the known predictors properly, multivariate analyses 
were performed. Even though the known predictors of a higher diagnostic yield were 
included in the retrospective and the prospective multivariate analyses, residual 
confounding could still exist.  
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Interactions 
Interactions appear when the effect of the association between the variable of interest 
and the outcome is inconsistent in different categories of the variable. To avoid 
confounding by interactions the data can be stratified and the effect visualised in 
different strata of the actual variable(190). There was one interaction between size of 
the lesion and use of endobronchial ultrasound in the prospective study. The stratified 
data revealed that endobronchial ultrasound had a lower diagnostic yield than 
conventional bronchoscopy for small lesions. The physicians performing the 
procedures in our study were just starting to learn how to use EBUS. Small lesions 
can be difficult to identify with EBUS and small movements on the guide sheath can 
displace the sampling position. Thus, the skills of the operator might be more 
important for small lesions than for large lesions. 
 
6.1.4 External validity 
The external validity evaluates whether the effects found in the study can be 
extrapolated to the target population under consideration or not(191). The inclusion 
and exclusion criteria and the description of the study population are important factors 
for external validity. To consider if studies of bronchoscopy are generally relevant, 
the characteristics of the included patient group, the physicians’ level of experience, 
and the cost level in the country being studied, should be analysed. 
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Inclusion criteria, exclusion criteria and patient characteristics 
 
Retrospective study 
A wide inclusion secured that all patients were evaluated. Only four cases where no 
sampling techniques were attempted were excluded. All patients with suspected 
malignant disease were included, not only those with a confirmed malignant 
diagnosis. The retrospective nature of the study made it possible to include cases at all 
levels of difficulty. We believe that the main results of bronchoscopy and the 
detection of predictors for a higher diagnostic yield in the current study population 
can be generalised to other centres where pulmonologists at various levels of 
experience perform the bronchoscopies. Only cases with the actual sampling 
techniques performed were included in the analysis of the optimal combination of 
techniques. Thus, the results might not be valid for all kinds of lesions. 
 
 Prospective study 
All cases where physicians found peripheral lesions on CT scans were to be included. 
Lesions that were deemed likely to be visible by bronchoscopy were to be excluded. 
The patient characteristics revealed that small lesions and hard-to-reach lesions were 
included. The non-included cases were not significantly different regarding size. The 
results can be generalised for patient populations where all kind of peripheral lesions 
are included. Previous studies indicated that endobronchial ultrasound should be 
reserved for small lesions(158) and patients with no CT bronchus sign should be 
excluded(164). The subgroup analyses from the current study did not support this 
selection. 
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The performing physicians’ level of experience 
The physicians that performed the bronchoscopies in the retrospective study and the 
prospective study were unselected and with various levels of experience. Most of the 
physicians were specialists in pulmonology, but trainees participated as well. The 
results of the study can be used in a setting where physicians at various levels of 
experience perform the bronchosopies. The results of the study may not be applicable 
to a practice where only selected sub-specialists in bronchoscopy or endoscopic 
ultrasound perform the procedures.  
The level of costs 
The cost-minimisation analysis in Paper 2 was dependent on the level of costs in the 
health care system being studied. The equipment costs may be similar in different 
countries, but the wages for the staff and the cost of the waiting time for the patient 
will probably be valued differently. The sensitivity analysis in Paper 2 demonstrated 
that the results can be generalised if the cost of one day in a day ward was valued 
above 311 euro, the total cost of brushing was below 83 euro and the total cost of 
EBNA was below 205 euro.  
The cost-effectiveness analysis in Paper 3 compared increase in cost to increase in the 
diagnostic yield. The willingness to pay for one additional positive sample will 
depend on how each health care system values the waiting time and the cost of an 
additional diagnostic procedure. The sensitivity analysis in Paper 3 revealed that the 
result can be generalised if the cost of brushing was below 142 euro. Acceptability 
analyses (not published) revealed that the result can be generalised if the willingness 
to pay for one additional positive sample was above 1350 euro and below 4350 euro.   
 
6.1.5 The STARD initiative and the CONSORT statement 
The Cochrane Diagnostic and Screening Test Methods Working Group initiated a 
working group for improved quality of reporting diagnostic studies in 1999. The 
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Standards for Reporting of Diagnostic Accuracy (STARD) was published in 
2003(192). STARD is a 25-item checklist that guides publications and help readers to 
judge the potential bias in studies. The checklist clarifies the selection of participants, 
recommends a description of methods and results. Paper 1 presented a retrospective 
cohort study that reported diagnostic accuracy; the STARD checklist guided the 
publication. Paper 1 did not describe test reproducibility (point 13) due to the 
consideration that it was unethical to repeat the bronchoscopy in the patients. The 
time from test to final diagnosis (point 17), was available, but not described in    
Paper 1.  
The Consolidated Standards of Reporting Trials (CONSORT) statement was 
published in 1996(193) and revised in 2001(194). The CONSORT statement intended 
to improve the reports from randomised controlled trials. It recommends that design, 
conduct, analysis, and interpretation should be available for the reader with complete 
transparency from the authors. The checklist describes a recommendation for the 
report of inclusion, a clarification of the outcome, a presentation of the sample size 
settled, and the randomisation process. The presentation of the results is summarised 
in the report. CONSORT recommends complete transparency from the authors for the 
type of analysis (intention-to-treat analysis or not) and for the number of subgroup 
analyses performed. A flow diagram visualise the recruitment of cases into the study. 
It describes the non-included cases, the excluded cases and the cases lost to follow up. 
Paper 3 was a randomised controlled trial, it presented the CONSORT flow diagram 
and the checklist guided the publication.  
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6.2 The main methological strengths and weaknesses in 
the current study 
6.2.1 The retrospective study 
Strengths  
Design: The retrospective cohort study included all plausible patients, thus sample-
selection bias was unlikely. 
Validity: A clinical gold standard controlled the results concerning the final diagnosis. 
Bias and confounding: The electronically obtained information avoided information 
bias. Multivariate analyses allowed for control of confounding factors based on the 
results of bivariate analyses.  
Statistical analysis: A cost-minimisation analysis compared the increase in cost to the 
increase in diagnostic yield. Sensitivity analyses found threshold values for costs and 
increases in diagnostic yields.  
External validity: It is possible to generalise the results to a practice where physicians 
at different levels of experience do the bronchoscopies.  
Weaknesses 
Design: A prospective cohort study allows for better planning of the bronchoscopy 
procedure, registers the possible predictors and standardise the choice of sampling 
techniques. The choice of sampling techniques, and whether to use fluoroscopy, was 
left to the physician to decide in the retrospective study.  
Validity: The gold standard was a confirmed pathological diagnosis for some patients, 
but only clinical follow up for other patients. A presumed effect of cytostatic drugs 
might hide a false positive bronchoscopy result in the clinical follow-up. 
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Bias and confounding: The non-standardised selection of sampling techniques made 
the result for each sampling technique prone for method-selection bias. Even though 
known predictors of a higher diagnostic yield adjusted the multivariate analysis, 
unknown factors could confound the results. 
Statistical analysis: The cost-minimisation analysis visualise all costs to a common 
end-point, but the result of a cost-effectiveness analysis is easier to compare to other 
studies. The cost-minimisation analysis does not reveal the price for one additional 
positive sample. 
External validity: The results cannot be generalised to a practise where only highly 
trained staff perform the procedures. The choice of sampling techniques and guidance 
was not standardised due to the retrospective nature of the study.  
 
6.2.2 The prospective study  
Strengths 
Design: The sample size calculation gave the inclusion number. The prospective 
design made it possible to plan the investigations and to do the bronchoscopies 
standardised. The prospective randomised study is the best study design to evaluate a 
diagnostic tool. The intention-to-treat analysis resembles a clinical situation where the 
equipment might fail during the procedure. 
Validity: A gold standard based on reconfirmation of the pathological results and 
clinical follow-up controlled the results. The reconfirmation made it possible to 
describe false positive cases. The clinical follow-up avoided exclusion of false 
negative cases. 
Bias and confounding: There was no difference in tumour size between the non-
included cases and the included cases. A randomised design and a multivariate 
analysis protected the analysis against confounding.  
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Statistical analysis: Paper 3 presented all subgroup analyses performed. A 
multivariate analysis controlled the bivariate analyses. The comparison of different 
combinations of sampling techniques compared the increase in cost to the increase in 
diagnostic yield. Sensitivity analyses revealed threshold values.  
External validity: The results are comparable to other centres for bronchoscopy of 
peripheral lesions when pulmonologists at various levels of experience perform the 
investigations.  
Weaknesses 
Design: The non-inclusion represented a threat for selection bias. The study did not 
evaluate the learning curve of the physicians.  
Validity: The gold standard was a confirmed diagnosis of malignancy in some cases 
and clinical follow-up in other cases. The clinical follow-up could have hidden false 
positive cases if the patient got treatment and the lesion disappeared. If the tumour 
was growing very slowly, false negative cases could theoretically be undetected.  
Bias and confounding: The cases not included represented a threat for selection bias. 
The selective evaluation of the cases with all sampling techniques performed was 
prone to selection bias.  
Statistical analysis: Introduction of diagnostic yield as an endpoint in the cost-
effectiveness analysis made it difficult to compare the results to other studies. The 
publication of subgroup analyses might be a risk for detecting p values below 5 % by 
chance (type I mistake). Paper 3 did not present a Bonferroni correction (division of 
the significance level by the number of subgroup analyses).  
External validity: The results might not be valid in a centre where highly trained staff 
performs the bronchoscopies. 
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6.3 Discussion of the main results 
6.3.1 The main recommendations for bronchoscopy in published 
reviews 
When the British Thoracic Society published their guidelines for bronchoscopy in 
2001, they distinguished between visible lesions and peripheral lesions(148).  The 
guidelines recommended a diagnostic yield above 80 % for visible lesions. They 
recommended fluoroscopy for localised peripheral lesions and the combination of 
biopsy, brushing and washing based on the papers from McLean et al.,(95) Gellert et 
al.,(62) and Mak et al.(78) The guidelines did not recommend TBNA or curettage.  
Schreiber et al. described the diagnostic yield of different sampling techniques for 
endobronchial visible lesions and for peripheral lesions in 2003(48). The size of the 
peripheral lesions was a predictor for the diagnostic yield. Few of the studies in 
Schreiber’s report included all patients with suspected lung cancer(48). 
 
Rivera et al. recommended bronchoscopy for central lesions and transthoracic needle 
aspiration for peripheral lesions in 2003. The paper recommended re-evaluation of 
benign results from central lesions to avoid false negative cases. The updated 2007 
paper recommended an EBUS  radial probe as the diagnostic approach for lesions 
below 2 cm when performed by expert hands(49).     
Ernst et al. published the recommendations for radial EBUS probe in 2003(46). EBUS 
was an extraordinarily safe procedure to visualise lesions, to describe tumour invasion 
and for differentiation between vascular and non-vascular structures. The paper 
recommended that trainees performed at least 50 procedures with EBUS with balloon 
to establish competency of the anatomic structures of mediastinum, but did not 
recommend a number for competence in peripheral lesions.  
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Chhajed et al. recommended conventional bronchoscopy with fluoroscopy first for 
peripheral lesions. If the result was negative, EBUS, navigation or CT-guided 
sampling was recommended(195).  
When Herth et al. described the future of bronchoscopy in 2006 he described 
endobronchial ultrasound, electromagnetic navigation, and autofluorescence 
endoscopy as the recent developments in bronchoscopy(196). The paper 
recommended that the newest tools should be available and that specialists should 
have sufficient knowledge of the tools to improve the diagnostic yield and the exact 
staging of cancer. 
EBUS-TBNA and transoesophageal ultrasound-guided fine-needle aspiration are new 
complementary techniques that can reduce the need for mediastinoscopy(197).  
The current study published the diagnostic yield in endobronchial visible lesions and 
in peripheral lesions for physicians with various levels of experience. It evaluated 
predictors of a higher diagnostic yield and controlled the already recommended 
combination of sampling techniques. Among the different new development in 
bronchoscopy, this study evaluated endobronchial ultrasound with a miniprobe. 
  
6.3.2 Benign lesions 
The main challenge in bronchoscopy is to get a representative sample from malignant 
disease in the lung. Rivera et al. and Schreiber et al. included only detection rates for 
cancer in the summaries of published evidence(48;49). It is possible to get a final 
diagnosis by bronchoscopy for some benign lung tumours. An answer from the 
pathological department with hamartoma or tuberculosis is probably a definite 
diagnosis, but inflammation can be malignant disease. 136 cases in the retrospective 
study had at least one sample with inflammation, 127 (93%) of these cases had a final 
malignant diagnosis. None of the benign cases in the retrospective or the prospective 
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study got a final diagnosis by the first bronchoscopy. The benign cases were included 
in the cost analyses because the recommended combination of sampling techniques 
will be used in benign and malignant lesions.    
 
6.3.3 Diagnostic yield in bronchoscopy 
Endobronchial visible lesions 
The recommended diagnostic yield of 80 %(148) in visible lesions is probably 
possible to achieve. The average detection rate for cancer in the studies presented in 
Table 2 was 4022/4782 (84 %). Figure 13 visualises the detection rate for cancer in 
papers with experienced physicians and from studies with physicians with various 
levels of experience. The level of experience did not predict the detection rate  for 
cancer in visible lesions.  
 
Figure 13: Detection rates for cancer in endobronchial visible lesions 
A) Various levels of experience
B) Experienced physicians
C) Level of experience not described
Sum all papers
1,0000,8000,6000,4000,200
 
The  papers included in Figure 13: A(56;68;113;117;124;134), B(67;78;107;109;125;136), and C(51-55;62-
64;70;71;80;87;91;92;97;98;103;105;106;111;116;129;140;146) 
 
The papers published after 2004 had detection rates for cancer above 80 % for visible 
lesions(106;116;117;124;125;129;136;140). Even though Paper 1 presented a 
detection rate for cancer of 77 %, slightly below the recommended, selected cases in 
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Paper 2 had a detection rate for cancer of 90 % when biopsy, brushing, and EBNA 
was performed by physicians with various levels of experience.  
Peripheral lesions not visible by bronchoscopy  
There is no recommended minimum diagnostic yield for peripheral lesions. The 
average detection rate for cancer was 69 % in a summary published in 2003 by 
Schreiber et al.(48) and 78 % in a the summary from Rivera et al.(49). Figure 14 
visualises that the results from the peripheral lesions depend on the physicians’ 
experience. Visible lesions are easy to detect and to sample, the path to peripheral 
lesions can be hard to identify.  
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Figure 14: Detection rates for cancer in peripheral lesions 
A) Various levels of experience
B) Experienced physicians
C) Level of experience not described
D) Virtual navigation without EBUS
Sum all papers
1,0000,8000,6000,4000,200
 
The papers included in Figure 14: A(56;100;113;117;132;134), B(67;74;78;88;94;115;119;125;137), C(50-
54;58;59;63;64;70;73;80;82-85;87;90;92;93;96;99;103-105;111;112;114;122;142;143;146), and 
D(110;118;121;123;126;138;139;145) 
 
The average detection rate for cancer in papers presented in Table 2 was 4179/6190 
(68 %) for peripheral lesions. Paper 1 presented a detection rate for cancer of 17 %. 
The main reasons for the difference between the results from our study and in the 
previously published studies were probably the use of fluoroscopy, the physicians’ 
levels of experience, and the difference in selection of patients. Figure 15 displays the 
difference in results from studies with fluoroscopy and studies without fluoroscopy.  
 
Figure 15:  The effect of guidance on the detection rate for cancer in peripheral 
lesions 
A) Fluoroscopy for some cases
B) Without fluoroscopy
C) Fluoroscopy not described
D) With fluoroscopy
E) With virtual navigation
F) CT guided bronchoscopy
1,0000,8000,6000,4000,200
 
The papers included in Figure 15: A(54;84;134), B(63;70;78;103;104;125), 
C(51;64;73;92;96;105;113;114;146), D(50;52;53;56;58;59;67;74;82;83;85-
88;90;93;94;99;100;111;112;115;117;122;132;137;142), E(110;118;121;123;126;138;139;145), and 
F(119;143) 
 
 99 
Paper 1 was from a retrospective study where the physicians individually decided on 
the sampling techniques and the use of fluoroscopy. The physicians used fluoroscopy 
in only 48/131 (37 %) of the cases. The detection rate for cancer was 17/48 (35 %) 
with fluoroscopy and 4/83 (5 %) without fluoroscopy. This result was comparable to 
the results presented in the Scottish multicentre study with a detection rate for cancer 
of 9 %(95). Paper 3 controlled the results from Paper 1 performed with fluoroscopy. 
Physicians in the non-EBUS group had a detection rate for cancer of 44 % when 
fluoroscopy guided the biopsies and brushings. This is comparable to the average 
results from studies where physicians with various levels of experience performed the 
bronchoscopies (Table 2: 246/501 (49 %)).  
A weakness of many previous reports was the lack of description of the physicians’ 
level of experience. Another weakness was the selective inclusion of patients. Some 
reports included only patients with a histological proven malignant diagnosis(51;56-
58;61;63;64;66;67;69;70;72;81;92;93;101;105;108;111;112;125;131;146), others only 
those with some specified sampling techniques applied(82;85-87;104;130;131;137). 
Lesions had to be visible by fluoroscopy in one report(115), other reports included 
only small lesions below 3 cm(61;76;108;127;128;131). These selections might have 
influenced the diagnostic yields. The diagnostic approach to small peripheral lesions 
is different from study centre to study centre. Some try to take biopsies from these 
difficult-to-reach lesions; others only do washings or refer the patients directly to CT-
guided biopsy or operation. The current study included all small peripheral lesions. 
Other studies might have excluded these lesions without reporting the exclusion.  
The studies presented in Table 2 have shown that a detection rate for cancer in 
peripheral lesions of 70 % is possible to achieve when experienced physicians 
perform the bronchoscopies in selected patients. Paper 1 and Paper 2 suggest that a 
detection rate for cancer of 40 % is a more realistic estimate for a situation where 
physicians at various levels of experience perform the bronchoscopies in an 
unselected patient sample.   
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6.3.4 Predictors of a higher diagnostic yield in bronchoscopy 
Studies published before initiation of the current study evaluated predictors of a 
higher diagnostic yield in bivariate analyses. The main weakness of those analyses 
was the possibility for other factors to confound the results. Diette et al. presented a 
multivariate analysis, but the analysis was not adjusted for size or endobronchial 
visibility(102). Size and endobronchial visibility were significant predictors of a 
higher diagnostic yield in the multivariate analysis presented in Paper 1. After this 
publication, Boonsarngsuk et al. presented a multivariate analysis with a similar 
result(141). Botana-Rial et al. and Sejo et al. excluded the visible lesions and 
presented multivariate analyses for predictors of the diagnostic yields in peripheral 
lesions(142;145). CT bronchus sign and size were significant predictors in Bontana-
Rial et al.’s study without navigation(142) while Sejo et al. found CT bronchus sign 
to be the only significant predictor in bronchoscopy with navigation(145).CT 
bronchus sign is the presence of an endobronchial pathway to the lesion. When a 
physician uses the CT scan to plan the bronchoscopy, a lesion with a bronchial branch 
straight from the main bronchus is regarded as easy-to-reach. Yoshikawa et al. 
presented endobronchial difficulty in three categories (clear, possible, and 
impossible). The current study tried to design a less subjective classification based on 
how many bronchial divisions the sampling device had to pass beyond the visual 
field. Paper 3 divided endobronchial difficulty into four categories. (I: a bronchial 
branch straight to the lesion, II: no direct path to the lesion, but one or two divisions 
to pass beyond the visible divisions, III: no direct path to the lesion, but three or more 
divisions to pass beyond the visible divisions, and IV: no bronchial branch leading to 
the lesion). Endobronchial difficulty was significant in bivariate and multivariate 
analyses. In the analysis of the non-EBUS group in Paper 3, size in four categories 
(<2cm, 2-3cm, 3-4cm, and >4cm) was significant in a bivariate analysis, but not 
significant in a multivariate analysis (data not presented in Paper 3). Based on results 
from Paper 1, Paper 3 and the multivariate analyses from other publications, data 
should be analysed separately for endobronchial visible lesions and for peripheral 
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lesions. In peripheral lesions, endobronchial difficulty or CT bronchus sign is the 
most important predictor of the diagnostic yield, the effect of size is uncertain.     
 
6.3.5 The optimal combination of sampling techniques in 
bronchoscopy 
Paper 2 recommended biopsy, TBNA, and brushing for endobronchial visible lesions 
based on a cost-minimisation analysis. Paper 3 recommended biopsy and brushing for 
peripheral lesions based on a cost-effectiveness analysis. Studies published after the 
initiation of the current study recommended different combinations of sampling 
techniques for peripheral lesions. The recommendations have been biopsy, TBNA, 
and brushing(116), biopsy and washing(124), biopsy and brushing or washing(117), 
biopsy, brushing, and washing(136), biopsy, brushing, and TBNA(116), biopsy, 
washing, and TBNA(120), or transbronchial catheter aspiration and biopsy(137). 
Cryoprobe biopsy has been recommended for visible lesions(140;144), while hot 
biopsy did not give additional value(129). Most papers compare the diagnostic yields 
without any analyses of the costs. Govert et al. presented a cost-effectiveness analysis 
before the initiation of the current study. The end-point was reduced quality days(91). 
The analysis recommended a combination of biopsy and brushing or washing for 
endobronchial visible lesions. Biopsy, brushing, and washing were analysed. Reduced 
quality days is not a widely accepted end-point. The willingness to pay for a reduced 
quality day is hard to estimate. A sensitivity analysis revealed that brushing or 
washing had to increase the diagnostic yield with 3 % to be cost-effective.  
Van der Drift et al. presented a cost-minimisation analysis in 2005. The title indicated 
a cost-effectiveness analysis, but the study was actually a cost-minimisation analysis 
of the addition of washing or brushing to biopsy(117). The study recommended a 
combination of biopsy and brushing or washing for visible lesions. For peripheral 
lesions, the combination of biopsy and washing was most economical. The paper did 
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not present sensitivity analyses of the results. A cost-minimisation analysis reveals the 
least costly strategy to a common end-point, a cost-effectiveness analysis might be 
better(198). When a centre wants to interpret the results from the economical 
analyses, the sensitivity analyses might be more valuable than the main results. Paper 
2 recommended biopsy, EBNA, and brushing for endobronchial visible lesions. The 
cost of brushing had to be below 83 euro and brushing had to increase the diagnostic 
yield with 2 % to be economical. The cost of brushing was estimated to 43 euro in 
Paper 2. Previous studies estimated the cost of brushing to 177$(91) and 103$(117) 
(approximately 70-120 euro). The increase in the diagnostic yield of brushing 
compared to biopsy alone was 3 % in Paper 2. An increase in the diagnostic yield 
above 2 % with brushing have been demonstrated in many 
studies(54;91;95;97;106;107;116). The cost of EBNA had to be below 205 euro and 
EBNA had to increase the diagnostic yield with 5 %. The cost of EBNA was 
estimated to 159 euro in Paper 2. One previous study estimated the cost of EBNA to 
174$(117) (approximately 120 euro). The increase in the diagnostic yield of EBNA 
was 7 % in Paper 2. Other studies reported an increase above 5 % of 
EBNA(60;97;116;117). The cost of a repeated procedure had to be at least 1786 euro 
for the conclusion to be true.  
The current study and the other published studies recommend the use of biopsy. 
Biopsy is inexpensive and has a high diagnostic yield. Even though the current study 
has analysed costs and diagnostic yields of different additional sampling techniques, 
there is still uncertainty regarding some parts of the conclusion. Increasing the 
number of biopsies was not compared to the addition of other sampling techniques. 
The study protocol recommended four biopsies, but Gellert et al. recommended 
five(62), Popovich et al. recommended one for visible lesions and up to ten for 
peripheral lesions(64). The studies did not compare a higher number of biopsies to an 
additional sampling technique.  
After the implementation of EBUS-TBNA for lymph nodes, there might be a 
possibility that it is better to sample the lymph nodes than to use time on the 
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peripheral lesions. Lymph node sampling will give the diagnosis and staging 
information in one procedure.  
The studies that included biopsy in the evaluation of sampling techniques 
recommended its use for central and peripheral lesions. The current study indicated 
that TBNA and brushing gave additional value for central lesions and recommended 
biopsy and brushing for peripheral lesions.    
 
6.3.6 Endobronchial ultrasound 
The current study evaluated visualisation of the lesions by EBUS and the physicians’ 
ability to get a proper diagnostic sample from the lesion with EBUS.  
Visualisation of the lesions 
The optimal position for the EBUS probe is inside the lesion. When the EBUS probe 
is inside the lesion, the ultrasound picture shows the lesion surrounding the probe 
(Figure 16). EBUS can visualise the lesion from a bronchial branch adjacent to the 
lesion (Figure 16), but the position is not optimal for sampling(160;163;170).  
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Figure 16: Visualisation by EBUS from inside a lesion and adjacent to a lesion 
 
  Inside the lesion    Adjacent to the lesion 
 
EBUS visualised the lesions from inside in 37 of 80 (46 %) of the malignant cases. 
The EBUS probe was adjacent to the lesion in additional eight cases. None of the 
cases with the ultrasound probe adjacent to the lesions got the diagnosis by the first 
bronchoscopy. The overall visualisation rate was 1568/1963 (80 %) in published 
studies (Figure 17). 
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Figure 17: Visualisation rates by EBUS in published papers 
 
A) Various levels of experience
B) Experienced physicians
C) Level of experience not described
D) EBUS combined with navigation
Sum all papers
1,0000,8000,6000,4000,200
 
The papers included in Figure 17: A(171;175), B(152;154;158;159;161;163;168;174), 
C(15;16;153;155;160;164;166;167;169;170;172) and D(156;157;162;165;173) 
 
Huang et al. analysed the predictors of a higher visualisation rate(170). Lesion size 
and malignant disease were significant in a multivariate analysis. Endobronchial 
difficulty or CT bronchus sign was not analysed. The size of the lesion was an 
important predictor for the visualisation rate in the current study. The visualisation 
rate was 38/71 (54 %) for lesions above 3 cm, compared to 13/46 (28 %) for lesions 
below 3 cm (p<0.01). The endobronchial difficulty also predicted the visualisation 
rate in a bivariate analysis. The visualisation rate was 62 % in cases with a bronchial 
branch going straight to the lesion, 50 % if there were 1-2 divisions to pass, 42 % if 
there were more than 3 divisions to pass and 22 % in those with no bronchial branch 
going towards the lesion (p=0.05).  
The physicians’ ability to manipulate the miniprobe into the correct bronchial branch 
will probably depend on experience. Most of the previous studies have been with 
experienced physicians(152;154;158;159;161;163;168;174).                                 
Some studies did not report the physicians’ level of 
experience(15;16;153;155;160;164;166;167;169;170;172). In addition to the current 
study, Oki et al. reported results from physicians with various levels of 
experience(171). Oki et al combined EBUS with an ultrathin bronchoscope and had a 
very high visualisation rate (92 %). The paper does not describe whether all attending 
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pulmonologists performed the investigations or if only selected physicians did. The 
attending physicians in the paper from Oki et al. were pulmonologists or supervised 
pulmonary residents.  
The inclusion into the different studies will probably affect the visualisation rate. No 
studies included only large lesions, but there is a possibility that some studies 
excluded lesions without any bronchial branches into the lesions. Some institutions do 
not consider such lesions for diagnostic bronchoscopy. The main reason for the low 
visualisation rate in the current study was probably the design where all physicians 
who attended the bronchoscopy lab performed the investigations. Another explanation 
might be the wide inclusion of all kinds of lesions including those with no bronchial 
branch towards the lesions.  
Detection rate for cancer 
Detection rate for cancer depends on the physicians’ ability to localise the lesion with 
EBUS and the ability to remove the miniprobe and to get the sampling device back 
into the correct position. The detection rate for cancer was 36 % with EBUS in the 
current study, 62 % in the lesions visualised by EBUS and 17 % in the cases not 
visualised by EBUS. The aim of the study was to achieve an average diagnostic yield 
of 60 % in the EBUS group. The average diagnostic yield in the publications from 
Table 3 was 752/1092 (69 %). Only Oki et al. published a paper from physicians with 
various level of experience. The detection rate for cancer was  80 % with an ultrathin 
bronchoscope in the paper from Oki et al.(171). Figure 18 displays the results from 
the studies in Table 3. 
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Figure 18: Detection rates for cancer with EBUS in peripheral lesions 
A) Various levels of experience
B) Experienced physicians
C) Level of experience not described
D) EBUS combined with navigation
Sum all papers
1,0000,8000,6000,4000,200
 
The papers included in Figure 18: A(171;175), B(154;158;159;163;168;174), C(153;155;164;166;170), and 
D(156;162;165;173) 
 
The low detection rate for cancer was due to a low visualisation rate. A design with 
fewer physicians might have given a higher visualisation rate and a higher .  
Some of the other studies had advantages like an ultrathin bronchoscope(171) or 
navigation(157;162;165;173). Use of fluoroscopy did not affect the results of the 
studies. The average detection rate for cancer was 752/1092 (69 %) in all studies with 
EBUS compared to 178/286 (62 %) in the studies where fluoroscopy guided the 
EBUS miniprobe(16;153;154;156;167;171;174;175). Studies with a guide sheath had 
an average detection rate for caner of 253/429 (59 %)(15;16;153;154;156;165-
168;174;175).  
When the lesions were visualised, the physicians removed the miniprobe and left the 
guide sheath in front of the lesion. If the patient was coughing, the guide sheath could 
easily move away from the lesion. Thus, studies performed with general anaesthesia 
would have the advantage of the patient not moving at all(162;173). Use of the guide 
sheath was a possible explanation for the slightly lower detection rate for cancer in 
the EBUS group compared to the non-EBUS group. The guide sheath was useful 
when EBUS visualised the lesions. The sheath guided the sampling devices towards 
the lesion with a detection rate for cancer of 62 % in visualised lesions. However, per 
protocol, our physicians also used the guide sheath for sampling from lesions not 
visualised by EBUS. Sampling without a guide sheath with a wider sampling area 
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might give better results for these lesions. Eberhardt et al. have published a paper with 
suction from a catheter close to the lesion(173). This sampling technique also samples 
from a wider area and is promising.  
In the present EBUS study, the physicians were in the beginning of the learning curve 
with EBUS. They were only able to achieve visualisation from inside the tumour in 
46 % of the lesions. When a malignant lesion was visualised, the detection rate for 
cancer was only 62 %.  
Comparison of EBUS and non-EBUS for peripheral lesions 
The main aim of Paper 3 was to compare the diagnostic yield of bronchoscopy with 
EBUS to the diagnostic yield of bronchoscopy without EBUS in a real-life setting. 
The predicted diagnostic yield in the non-EBUS group was 40 %, the detection rate 
for cancer in the study was 43 %. The detection rate for cancer in the EBUS group 
was 36 %, far from the predicted 60 %. Thus, there was no increase in the diagnostic 
yield with EBUS in a situation where physicians with various levels of experience 
performed the bronchoscopies. Subgroup analyses in Paper 3 showed that the 
physicians were able to get a very high detection rate for cancer with EBUS in easy-
to-reach lesions (89 %), but the detection rate for cancer was high also for easy-to-
reach lesions in the non-EBUS group (72 %, NS). We expected EBUS to be a good 
tool for hard-to-reach lesions, but in the current study, non-EBUS had higher 
detection rates for cancer if there were no bronchial branches going straight to the 
lesions. As discussed previously, the navigation towards the lesion can be 
complicated and learning might improve the results. For inexperienced physicians 
sampling without a guide sheath from a wider area was better than localised sampling 
with EBUS. A guide sheath in a difficult position might easily slip away during 
breathing or coughing. The multivariate analysis in Paper 3 found an interaction 
between size and use of EBUS. For lesions below 3 cm the detection rate for cancer 
in the EBUS group was lower than the detection rate for cancer in the non-EBUS 
group. This result is contrary to the results from experienced physicians where the 
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EBUS group had a higher diagnostic yield than the non-EBUS group in small 
lesions(152;158).  
Few studies have compared the diagnostic yield with EBUS to the diagnostic yield 
without EBUS in peripheral lesions. The first study by Herth et al. was from the 
Heidelberg group(152). Although not described in the paper, very experienced 
physicians performed the bronchoscopies with the patients in general anaesthesia. The 
paper did not report the non-inclusion or whether hard-to-reach lesions with no 
bronchial branches to the lesions were included or not. The study had a crossover 
design where the physician performed a bronchoscopy with EBUS and without EBUS 
in the same patient. Having first determined the position by EBUS might have biased 
the results in the non-EBUS group. The study achieved a high diagnostic yield in the 
EBUS group (80 %), but there was no significant increase compared to the non-EBUS 
group (76 %). There was a tendency for EBUS to be better for small lesions. The 
Heidelberg group has shown high detection rates for EBUS in lesions invisible by 
fluoroscopy (159;168) and when EBUS was combined with navigation(157;162). 
Eberhardt et al. found a significant higher detection rate for the combination of 
navigation and EBUS compared to each method alone.   
Yang et al. published a paper in 2004 with a comparison between EBUS and non-
EBUS. This was a retrospective study of the patients investigated before the 
introduction of EBUS compared to those investigated with EBUS. There was a 
significant increase in detection rate for cancer. The detection rate was 43 % without 
EBUS and increased to 66 % with EBUS. The study had a wide inclusion, but did not 
describe the level of experience of the performing physicians. 
Shirakawa et al. compared EBUS performed by two experienced physicians to a 
historical control group where the two physicians performed the bronchoscopies(154). 
Their conclusion was that EBUS improves the diagnostic accuracy, but the detection 
rate for cancer was 71 % in the EBUS group and 70 % in the non-EBUS group.   
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Paone et al. performed a randomised trial with sample size calculation, but without a 
conclusion for the mnumber needed in the study(158). Two experienced physicians 
performed all procedures. They investigated all patients with bronchoscopy before the 
inclusion. 386 of 799 patients were excluded because of low compliance. Compliance 
was defined as the supposed ability to accomplish a follow up algorithm. The study 
found a significant increase in the detection rate for cancer. The detection rate for 
cancer increased from 55 % in the non-EBUS group to 79 % in the EBUS group. 
Subgroup analyses revealed there was no increase in the diagnostic yield with EBUS 
for lesions above 3 cm. This study has shown that EBUS can increase the detection 
rate for cancer in small lesions when performed by experienced physicians in selected 
patients. 
Figure 19 is a comparison of the average detection rate for cancer in studies without 
EBUS (Figure 14) and the detection rate for cancer in studies with EBUS (Figure 18). 
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Figure 19 Comparisons of studies with EBUS and studies without EBUS 
A1) Various levels of experience without EBUS
A2) Various levels of experience with EBUS
B1) Experienced physicians without EBUS
B2) Experienced physicians with EBUS
C1) Level of experience not described (without EBUS)
C2) Level of experience not described (with EBUS)
D1) Virtual navigation without EBUS
D2) EBUS combined with navigation
Sum(I): All papers without EBUS
Sum(II): All papers with EBUS
1,0000,8000,6000,4000,200
 
The papers included in Figure 19: A1(56;100;113;117;132;134), A2(171;175),  
B1(67;74;78;88;94;115;119;125;137), B2(154;158;159;163;168;174), C1(50-54;58;59;63;64;70;73;80;82-
85;87;90;92;93;96;99;103-105;111;112;114;122;142;143;146), C2(153;155;164;166;170), 
D1(110;118;121;123;126;138;139;145), and D2(156;162;165;173) 
 
The average detection rate for cancer was 4179/6190 (68 %) in studies without EBUS 
and 752/1092 (69 %) in studies with EBUS. There were no large differences in results 
of the studies with EBUS and the non-EBUS studies for the subgroups displayed in 
Figure 19. The comparison did not adjust the results of the studies for size or 
endobronchial difficulty. All studies that reported detection rates for cancer in 
peripheral lesions were included regardless of inclusion criteria. There might be a 
possibility for bias because some studies of EBUS only included small 
lesions(162;163). If only small lesions or hard-to-reach lesions were included, a lower 
diagnostic yield might be expected. The average detection rate for cancer for lesions 
below 3 cm were similar in studies with EBUS (304/481 (63 %)) and in studies 
without EBUS (407/659 (62 %)). (Values from Table 2 and Table 3) 
One randomised trial found an increase in diagnostic yield with EBUS for small 
peripheral lesions when experienced physicians performed EBUS in selected 
patients(158). However, a comparison of all published studies did not reveal any 
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significant benefit of EBUS. There was no increase in the diagnostic yield with EBUS 
performed by physicians at various levels of experience in the current study. 
 
6.4 Conclusions 
Endobronchial visibility and lesion size were predictors for a higher diagnostic yield 
in the current study of bronchoscopy. A novel classification of endobronchial 
difficulty, presented in Paper 3, was a significant predictor in a separate analysis of 
peripheral lesions. The optimal combination of sampling techniques was biopsy, 
brushing and EBNA for visible lesions. For peripheral lesions, biopsy and brushing 
was the optimal combination. There was no increase in the diagnostic yield by use of 
EBUS performed by physicians at various levels of experience.  
 
 113 
7. Suggestions for future research 
7.1.1 Navigation 
Previous studies found an advantage of the Superdimension navigation system 
combined with EBUS(162). There is a need of cost-effectiveness studies for these 
devices. The navigation probes are expensive and disposable with design for one-time 
use only. The EBUS probe is vulnerable. LungPoint has developed a new navigation 
system(199) that reads the bronchoscopy picture. The system is expensive to buy, but 
does not have single use expenses. The usefulness of the LungPoint system and 
virtual bronchoscopy systems integrated in the regular CT working stations, are 
possible platforms for future research on bronchoscopy for visualization and sampling 
from peripheral lesions.  
 
7.1.2 Bronchography 
Catheter bronchography is an inexpensive and simple method to display the bronchial 
branches. The physician infuses diluted contrast medium (like Iohexol) through a 
catheter into the actual bronchial segments. Two previous studies had very high 
diagnostic yields with bronchography for small lesions below 2 cm(61;76). Catheter 
bronchography is a possible intervention that can be tested in future studies.     
 
7.1.3 BAL 
The current study did not evaluate BAL in the diagnostic approach. BAL is the 
installation of 50 ml saline into the actual bronchial branch. Some studies have shown 
good results of BAL for peripheral lesions(66;104;114). The possibility to use BAL 
alone for difficult-to-reach lesions is a suggestion for future research.  
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7.1.4 Curettage 
The current study used the curette to manipulate the guide sheath into the correct 
position. Some studies had good results of the curette as a sampling 
technique(53;61;76;110;112). The curette as a sampling technique is a possible device 
that needs further evaluations in future studies. 
 
7.1.5 Catheter aspiration 
Eberhardt et al. has shown promising results for catheter aspiration from the area of 
the lesions(162). The technique is promising, but future studies must evaluate its 
potential.  
 
7.1.6 EBUS 
The current study did not recommend EBUS for inexperienced physicians when the 
lesions were small or hard-to-reach. Easy-to-reach lesions above 3 cm have a good 
diagnostic yield with fluoroscopy, biopsy, and brushing regardless of the use of 
EBUS. The usefulness of EBUS for small lesions with experienced physicians is still 
not settled even though one randomised study has shown promising results(158).   
 
7.1.7 The diagnostic approach to visible and peripheral lesions 
Based on the current knowledge all pulmonologists can sample visible lesions with 
good results. The current study recommended biopsy, brushing, and EBNA for visible 
lesions, but future studies can evaluate whether a higher number of biopsies can 
replace brushing or EBNA. Physicians with various levels of experience can sample 
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easy-to-reach lesions above 3 cm with fluoroscopy, biopsy, and brushing. Hard-to-
reach lesions and lesions below 3 cm are possibly to be reserved for experienced 
physicians. We need future studies to settle if catheter bronchography, navigation, 
EBUS, curette, BAL or catheter aspiration are cost-effective devices for the 
experienced physician. Future studies can settle whether bronchoscopy or CT-guided 
biopsy is preferable for lesions without any bronchial branches directly to the lesions. 
The introduction of EBUS-TBNA for lymph nodes might change the need for 
sampling from peripheral lesions.  
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